<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomed Sci</journal-id><journal-id journal-id-type="iso-abbrev">J. Biomed. Sci</journal-id><journal-title-group><journal-title>Journal of Biomedical Science</journal-title></journal-title-group><issn pub-type="ppub">1021-7770</issn><issn pub-type="epub">1423-0127</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6800501</article-id><article-id pub-id-type="publisher-id">572</article-id><article-id pub-id-type="doi">10.1186/s12929-019-0572-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>M2e-based universal influenza vaccines: a historical overview and new approaches to development</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mezhenskaya</surname><given-names>Daria</given-names></name><address><email>dasmez@iemspb.ru</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2801-1508</contrib-id><name><surname>Isakova-Sivak</surname><given-names>Irina</given-names></name><address><phone>812-234-4292</phone><email>isakova.sivak@iemspb.ru</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Rudenko</surname><given-names>Larisa</given-names></name><address><email>virus@iemspb.ru</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0482 8489</institution-id><institution-id institution-id-type="GRID">grid.465311.4</institution-id><institution>Department of Virology, </institution><institution>Institute of Experimental Medicine, </institution></institution-wrap>12 Acad. Pavlov Street, St. Petersburg, 197376 Russia </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>26</volume><elocation-id>76</elocation-id><history><date date-type="received"><day>20</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>1</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The influenza A virus was isolated for the first time in 1931, and the first attempts to develop a vaccine against the virus began soon afterwards. In addition to causing seasonal epidemics, influenza viruses can cause pandemics at random intervals, which are very hard to predict. Vaccination is the most effective way of preventing the spread of influenza infection. However, seasonal vaccination is ineffective against pandemic influenza viruses because of antigenic differences, and it takes approximately six months from isolation of a new virus to develop an effective vaccine. One of the possible ways to fight the emergence of pandemics may be by using a new type of vaccine, with a long and broad spectrum of action. The extracellular domain of the M2 protein (M2e) of influenza A virus is a conservative region, and an attractive target for a universal influenza vaccine. This review gives a historical overview of the study of M2 protein, and summarizes the latest developments in the preparation of M2e-based universal influenza vaccines.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Influenza a virus</kwd><kwd>Influenza M2 ectodomain</kwd><kwd>Conserved protein</kwd><kwd>Cross-protection</kwd><kwd>Universal influenza vaccine</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006769</institution-id><institution>Russian Science Foundation</institution></institution-wrap></funding-source><award-id>19-15-00015</award-id><principal-award-recipient><name><surname>Rudenko</surname><given-names>Larisa</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par27">The extremely high variability in the antigenic properties of influenza virus is related to the structure of its genome that allows reassortment and the structural flexibility of the viral glycoproteins, which tolerate amino acid residue substitutions in the major antigenic sites without loss of function. Often immunity raised against previously circulating variants is not capable of protecting against newly emerging drift variants. In addition, completely new antigenic variants of the influenza virus are occasionally introduced into the human population; since the population is immunologically naive to them, these viruses spread easily and can cause pandemics. These features of influenza infection explain why there is interest around the world in developing a universal influenza vaccine, which could induce a cross-reactive immune response to the most conservative parts of the viral proteins.</p><p id="Par28">Classic influenza vaccines commonly induce antibodies to the viral surface antigens, hemagglutinin (HA) and neuraminidase (NA), mainly to their immunodominant hypervariable regions. Constant antigenic drift allows the virus easily to escape the action of these antibodies, reducing the effectiveness of vaccination and leading to a need for annual updating of vaccine strains in the seasonal influenza vaccines [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR129">129</xref>]. The performance of seasonal influenza vaccines can be improved by increasing the speed of vaccine production and using new adjuvants and new vaccination strategies. However, these vaccines will not be able to protect against newly emerging pandemic influenza viruses because of significant antigenic differences. Potentially pandemic viruses have been identified and many vaccines, based on different approaches and platforms, have been developed against them [<xref ref-type="bibr" rid="CR133">133</xref>, <xref ref-type="bibr" rid="CR134">134</xref>]. However, these vaccines also have narrow specificity and may not have cross-reactivity, even within a single subtype. There has, therefore, been significant interest in the development of new vaccines that would have a longer and wider spectrum of action [<xref ref-type="bibr" rid="CR9">9</xref>], and which would provide long-term protection not only against drifted variants of influenza A viruses of one subtype but also against viruses of other subtypes. One approach to expanding the spectrum of the protective action of influenza vaccines is to enhance the induction of cross-reacting immune response factors that target highly conserved antigens in influenza viruses of various subtypes [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. The influenza virion contains multiple conservative domains that, because of their functional significance, are rather weak immunogens; classical approaches to immunization are not able to induce a strong immune response to these sites.</p><p id="Par29">The broadly protective vaccines currently being developed can be divided into two groups.
<list list-type="order"><list-item><p id="Par30">Vaccines that induce antibodies to structurally conserved regions of viral proteins, such as the stalk domain of the hemagglutinin which is important for the penetration of the influenza virus into the cell [<xref ref-type="bibr" rid="CR63">63</xref>]; broadly immunogenic epitopes located at the contact surface between HA head domains [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR130">130</xref>]; the enzymatic site of NA, where the surface cell sialic acids are cut [<xref ref-type="bibr" rid="CR23">23</xref>]; and the ectodomain of the M2 protein (reviewed in this manuscript). Induced antibodies can both have a neutralizing function and participate in the process of antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis (ADCP), thereby accelerating the elimination of the virus from an infected organism [<xref ref-type="bibr" rid="CR126">126</xref>].</p></list-item><list-item><p id="Par31">Vaccines that induce a cross-reactive T-cell immune response to the conserved epitopes of the virion&#x02019;s internal proteins, such as nucleoprotein (NP) and M1 [<xref ref-type="bibr" rid="CR27">27</xref>]. This is supported by a strong correlation of CD8+ T cells specific to conserved viral epitopes with cross-protection against symptomatic influenza in the absence of cross-reactive neutralizing antibodies [<xref ref-type="bibr" rid="CR111">111</xref>].</p></list-item></list></p></sec><sec id="Sec2"><title>Historical aspects of studying M2 protein</title><p id="Par32">Most attempts to create a universal influenza vaccine have been based on the M2e epitopes. The first evidence of the existence of M2 protein was published in 1981 [<xref ref-type="bibr" rid="CR65">65</xref>]. Several groups had already shown that the influenza A virus has a segmented genome consisting of 8 elements [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. It was also known that the 8th mRNA encodes two proteins, NS1 and NS2 [<xref ref-type="bibr" rid="CR66">66</xref>], and that the nucleotide sequence of the 7th mRNA contains two open reading frames [<xref ref-type="bibr" rid="CR135">135</xref>], which were thought to encode the already discovered M1 protein and a previously unknown protein consisting of 97 amino acid residues [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par33">Further study using viral lysate labelling with [<sup>35</sup>S] methionine and subsequent separation in a polyacrylamide gel detected a new protein with greater electrophoretic mobility than the already known influenza A protein. Isolation of different mRNA segments followed by peptide synthesis in vitro produced a new peptide of similar molecular weight; it was concluded that the 7th segment of the mRNA of the influenza A genome and the new M2 protein were genetically related. RNA-RNA hybridization established that the 7th segment encodes M1 and M2 proteins [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par34">At first, M2 was detected only in infected cells [<xref ref-type="bibr" rid="CR65">65</xref>], and not in the influenza virions themselves, which made it possible to put forward an assumption about the specific location of this protein. On the basis of the amino acid sequence of M2 [<xref ref-type="bibr" rid="CR67">67</xref>], a hydropathy graph was constructed indicating the presence of a hydrophobic domain. Further study of the protein led to the conclusion that the C-terminus is located in the cytoplasmic space, while the N-terminal part of M2 is exposed at the viral surface [<xref ref-type="bibr" rid="CR69">69</xref>].</p><p id="Par35">The first monoclonal antibody to M2 (14C2) was obtained in 1988 as a result of the immunization of BALB/c mice with purified M2 protein along with Freund&#x02019;s adjuvant. A subsequent study of 14C2 showed that the antibody binds to the extracellular N-terminal region of M2 (M2e) [<xref ref-type="bibr" rid="CR140">140</xref>]. Currently, there is evidence that the binding site is a fragment of M2e from the 6th to the 15th residue [<xref ref-type="bibr" rid="CR128">128</xref>]. In 1998, it was shown that the 14C2 antibody is not able to inhibit the adsorption and penetration of influenza virus into cells, but is able to limit the growth of influenza A virus in vitro, though this restriction is highly strain dependent [<xref ref-type="bibr" rid="CR140">140</xref>]. Another M2e-specific monoclonal antibody was obtained in 1996. To this end, splenocytes from BALB/c mice immunized with the keyhole limpet hemocyanin-linked M2 peptide SLLTEVETPIRNEWGCRCND were fused with F23.1 hybridoma cells producing an immunoglobulin G2a (IgG2a) monoclonal antibody. The authors selected a monoclonal antibody (3F12), which not only had cross-reactivity to different influenza A strains, but could also bind to the T-cell receptor. It was also shown that such a bispecific antibody is able to limit the growth of influenza A virus in vitro (with less efficiency than 14C2) and redirect activated T-cells to eliminate infected cells [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par36">In 2003, another study was published in which rabbits were immunized with 4 peptides from the N-terminal section of M2, with overlapping areas: &#x00430;.a. 2&#x02013;24, &#x00430;.a. 2&#x02013;12, &#x00430;.a. 8&#x02013;18 and &#x00430;.a. 13&#x02013;24. Further study showed that they all produced antibodies capable of recognizing each of the four peptides. It has also been shown that antibodies recognizing the N-terminus of M2 (a.a 2&#x02013;12) have virus-neutralizing activity against both influenza A and B in vitro [<xref ref-type="bibr" rid="CR77">77</xref>]. The authors suggested that this part of M2 may contain one epitope that can induce antibodies with inhibitory activities against both viruses, but there is no additional evidence that could confirm that anti-M2e immunity can suppress influenza B virus replication. Later, the same group of scientists reported that a small area of M2 EVETPIRN (a.a. 6&#x02013;13) can produce antibodies 8C6 and 1B12, but their protective effect has not yet been sufficiently studied [<xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par37">One of the potential therapeutic antibodies is TCN-032, which has passed phase I and II clinical trials. TCN-032 recognizes the M2e2&#x02013;6 epitope [<xref ref-type="bibr" rid="CR37">37</xref>] and may provide immediate immunity against influenza A infection [<xref ref-type="bibr" rid="CR99">99</xref>]. Another potential therapeutic antibody is anti-M2e antibody Z3G1, which has been shown to protect mice applied therapeutically at different time points after infection [<xref ref-type="bibr" rid="CR128">128</xref>].</p><p id="Par38">Mutational analysis, crystallography analysis of the structure and nuclear magnetic resonance have established that M2 is a transmembrane protein, consisting of four &#x003b1;-helices. Each helix has two conservative residues (His37 and Trp41), which play an important role in the life cycle of influenza virus [<xref ref-type="bibr" rid="CR115">115</xref>]. Highly conserved and oxidized cysteine residues at positions 17 and 19 are responsible for the stabilization of the structure [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par39">The entire M2 protein can be divided into 3 parts: the N-terminal or extracellular domain (23 a.a., excluding the 1st methionine); the hydrophobic transmembrane domain (19 a.a.); and the C-terminal domain (54 a.a.). The extracellular domain of M2 (M2e) consists of 23 amino acid residues and is a highly conserved region in all influenza A viruses. One of the reasons for the low variability of M2e is its inability to induce an immune response in an infected organism [<xref ref-type="bibr" rid="CR11">11</xref>], so there is no selection pressure on the site. A more important reason is believed to be the genetic relationship between M2e and M1: a.a. 1&#x02013;9 of M2e and M1 are encoded by the same nucleotides in the same reading frame. Amino acids 10&#x02013;23 of M2e and a.a. 239&#x02013;252 of M1 are also encoded by the same RNA sequence but are translated in different reading frames [<xref ref-type="bibr" rid="CR51">51</xref>]. M1, in turn, is a highly conserved matrix protein with a countable number of currently known mutations [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par40">The whole of M2 is highly conserved, but its extracellular part is of the greatest interest as a potential antigen. We analyzed 27,253 human, 15,367 avian and 5379 swine individual sequences of influenza A virus M gene (obtained from the Influenza Research Database (<ext-link ext-link-type="uri" xlink:href="http://fludb.org">fludb.org</ext-link>)) and generated a phylogenetic tree using MAFFT [<xref ref-type="bibr" rid="CR55">55</xref>]. The tree was visualized using the Interactive Tree Of Life (iTOL) server [<xref ref-type="bibr" rid="CR76">76</xref>]. As shown on Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a, the M2e sequences of influenza A viruses have evolutionary diverged into several lineages mainly related to host species. The generated phylogenetic tree basically repeats the published analysis of Furuse et al. [<xref ref-type="bibr" rid="CR33">33</xref>], but in contrast to this study published before the 2009 pandemic, our analysis included a large number of sequences of H1N1pdm09 virus M gene, which is known to originate from the Eurasian avian-like swine H1N1 lineage [<xref ref-type="bibr" rid="CR109">109</xref>]. We selected six different lineages of M2e protein based on their phylogenetic relatedness and obtained consensus sequences for each lineage using UGENE Multiple Alignment software (Fig. <xref rid="Fig1" ref-type="fig">1</xref>b). As mentioned above, the first nine amino acids have the lowest variability for each analyzed group. The remaining residues have different percentage mutations for each origin; however, the residues Arg12, Trp15, Cys17, Cys19, Ser22 and Asp24 have the lowest frequency of mutations, which may reflect their functional significance. The only exception is the residue at 19th position in the swine influenza viruses that fall into lineage 2, in which Tyr dominated in this position (Fig. <xref rid="Fig1" ref-type="fig">1</xref>b). The slight difference between the consensus sequences is also significant for the choice of the appropriate sequence for a universal vaccine. For example, immunization of pigs with human M2e using different carriers did not protect the animals from the lethal swine subtype of influenza A virus [<xref ref-type="bibr" rid="CR41">41</xref>]. It has also been shown that monoclonal antibody 8C6, which protects mice against lethal challenge virus [<xref ref-type="bibr" rid="CR78">78</xref>], is able to recognize the consensus part of human M2e &#x0201c;EVETPIRN&#x0201d; sequence (&#x00430;.a. 6&#x02013;13), but not the consensus fragment of avian M2e &#x0201c;EVETPTRN&#x0201d; (a.a. 6&#x02013;13). Thus, it is possible that an amino acid substitution at the 11th position in avian M2e may allow avian influenza A virus to escape the immune response in humans [<xref ref-type="bibr" rid="CR79">79</xref>]. Based on our analysis of all available M2e sequences, in order to develop a M2e-based universal influenza vaccine we propose using four different consensus M2e protein sequences that will cover most human, avian and swine influenza A viruses (Fig. <xref rid="Fig1" ref-type="fig">1</xref>c). In contrast to previously published studies, we suggest using two different M2e sequences for human influenza viruses due to the significant variations between the human viruses isolated before the 2009 pandemic and the H1N1pdm09 viruses.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Analysis of M2e sequences of human, swine and avian influenza viruses. <bold>a</bold> Phylogenetic tree was generated from 27,253 human, 15,367 avian and 5379 swine individual sequences of influenza A virus M gene (obtained from the Influenza Research Database (<ext-link ext-link-type="uri" xlink:href="http://fludb.org">fludb.org</ext-link>)) using MAFFT. The tree was visualized using the Interactive Tree Of Life (iTOL) server. <bold>b</bold> Prevalence of amino acid residues in M2e protein of selected M2e lineages. The consensus sequences for each lineage were obtained using UGENE Multiple Alignment software. Residues with a frequency below 3% are indicated with (*). <bold>c</bold> Proposed consensus M2e sequences for the development of a universal influenza vaccine</p></caption><graphic xlink:href="12929_2019_572_Fig1_HTML" id="MO1"/></fig></p><p id="Par41">The structure of free M2e is currently unknown. However, a number of studies have obtained crystallographic data on the structures of &#x0201c;M2e&#x02009;+&#x02009;antibody&#x0201d;. Using the example of MAb65, MAb148, Fab148 and Fab65 antibodies, it has been shown that M2e can take at least two different conformations to increase its affinity. For example, interaction with Fab148 and MAb148 occurs through residues 2&#x02013;5, which play an important role in the interaction and form a &#x003b2;-turn. For interaction with MAb65, not only do residues 5&#x02013;8 form a &#x003b2;-turn, but also the whole M2e takes a U-shaped formation with a central Trp15 [<xref ref-type="bibr" rid="CR15">15</xref>]. For the formation of a stable complex with the Fab65 antibody, the importance of residues 10&#x02013;11 in M2e has been shown, while residues 6, 8 and 14 are responsible for hydrophilic interactions with MAb65 [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par42">Study of the structural features of the transmembrane domain of M2 (a.a. 18&#x02013;60) and nearby areas at pH&#x02009;7.5 revealed the presence of a nonstructural N-terminal region (a.a. 18&#x02013;23), a channel-forming transmembrane helix (a.a. 25&#x02013;46), a short flexible loop (a.a. 47&#x02013;50) and a C-terminal aliphatic helix (a.a. 51&#x02013;59) [<xref ref-type="bibr" rid="CR104">104</xref>].</p><p id="Par43">The 7th segment of the influenza A virus genome can be subjected to alternative splicing with the formation of M2 mRNA and mRNA3; the formation of M4 mRNA is also possible in some strains [<xref ref-type="bibr" rid="CR100">100</xref>]. This process can proceed independently of other influenza A virus proteins [<xref ref-type="bibr" rid="CR68">68</xref>] using only the host cell machinery. However, a number of papers have reported the control of M1 mRNA splicing using other influenza A virus proteins [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. Currently, it is known that NS1 provides the main regulatory function of the amount of M2 in infected cells [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR100">100</xref>], rather than polymerase proteins, as was previously thought [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>].</p></sec><sec id="Sec3"><title>Functions of M2 protein</title><p id="Par44">Currently, several biological functions of M2 protein are known. The first and most important is as a proton-selective channel or so-called viroporin [<xref ref-type="bibr" rid="CR97">97</xref>], which is formed by four fragments of H37xxxW41 [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]. Shortly after the influenza virus enters a cell as part of the endosome [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR132">132</xref>], M2 goes into an activated state triggered by the acidic environment inside the endosomes. Using the M2 protein, H<sup>+</sup> ions are transferred through the viral membrane into the virion (proton transfer occurs through the formation of the protonated state of His37 [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR125">125</xref>] and rotation of the indole of Trp41 [<xref ref-type="bibr" rid="CR118">118</xref>]). The influx of protons also leads to an influx of potassium and sodium ions (K<sup>+</sup> and Na<sup>+</sup>), which in turn lead to a change in the M1 conformation, and the viral RNA goes into a relaxed state [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. The low endosomal pH leads to conformational changes in the HA molecule, which in turn triggers the fusion of the virion membrane with the endosomal membrane. Further, the interaction between M1 and the ribonucleoprotein complex is weakened, which leads to the release of viral RNA into the cytosol [<xref ref-type="bibr" rid="CR14">14</xref>]. It has also been shown that the ionic imbalance in the cell, resulting from the operation of the M2 protein, is a signal for the formation of inflammatory activity in myeloid cells such as macrophages and dendritic cells [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par45">Another function of M2 is participation in the formation and budding of new influenza A virions. The study of this feature began with the discovery that viral replication is inhibited by antibodies that recognize the extracellular domain of M2, despite the small amount of M2 on the surface of influenza A virus [<xref ref-type="bibr" rid="CR83">83</xref>]. Using reverse genetics and mutational analysis, it has been shown that truncated forms of M2, or forms with mutations in the cytoplasmic tail, further reduce the level of free M1 in the cellular environment, which is required for the assembly and budding of new virions [<xref ref-type="bibr" rid="CR12">12</xref>]. It has also been shown that M2 protein mediates membrane budding and scission processes via a pathway that is independent of ESCRT (endosomal sorting complexes required for transport), unlike many other enveloped viruses [<xref ref-type="bibr" rid="CR101">101</xref>]. The major role in M2-mediated budding and scission processes is played by the amphipathic region (residues 45&#x02013;62), which interacts with various host cell proteins involved in remodeling the cell membrane (reviewed in [<xref ref-type="bibr" rid="CR81">81</xref>]).</p><p id="Par46">Furthermore, the M2 of influenza A virus is a mediator of macroautophagy inhibition at the stage of fusion of autophagosomes and lysosomes, which causes a subsequent increase in cell death as a result of influenza infection and an increase in viral antigen yield [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par47">The functional ortholog of influenza A virus M2 is M2 from influenza B virus (BM2), which also carries electrons through the membrane [<xref ref-type="bibr" rid="CR86">86</xref>], interacts with the influenza B matrix 1 protein [<xref ref-type="bibr" rid="CR127">127</xref>], crucial for virus assembly [<xref ref-type="bibr" rid="CR50">50</xref>], and has an HxxxW motif in its transmembrane part [<xref ref-type="bibr" rid="CR93">93</xref>]. However, the sequences of M2 and BM2 have significant differences. For example, the extracellular part of BM2 consists of only seven amino acid residues [<xref ref-type="bibr" rid="CR102">102</xref>] (the consensus for human BM2e according to analysis of 9011 sequences from the Influenza Research Database is &#x0201c;MLEPFQI&#x0201d;). Because of its small size, BM2e is most likely not able to establish a protective immune responses [<xref ref-type="bibr" rid="CR102">102</xref>].</p><p id="Par48">A functional analogue of M2 is the M42 protein, which is obtained by splicing the 7th segment of the influenza A virus genome in some influenza strains [<xref ref-type="bibr" rid="CR136">136</xref>].</p><p id="Par49">Despite the importance of the M2 functions, it is not an essential protein for influenza A virus. In laboratory practice, so-called &#x0201c;M2 null&#x0201d; viruses have been obtained by various modifications of stop codons [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]. All of these viruses were viable but had a reduced replication level [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR137">137</xref>]. Moreover, an M2-deficient single replication (M2SR) virus has been generated and evaluated as a possible candidate for live influenza vaccine. The M2SR vaccine was able to infect cells and express all viral proteins except M2, without generating progeny virus [<xref ref-type="bibr" rid="CR103">103</xref>]. This vaccine platform proved efficient in protecting animals (mice and ferrets) against heterologous/heterosubtypic influenza virus infections [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], and is now undergoing phase I clinical trials (clinicaltrials.gov&#x000a0;NCT03553940; NCT02822105).</p></sec><sec id="Sec4"><title>Protection mechanisms of M2e-based vaccines</title><p id="Par50">Despite the small size of M2e, many questions about this protein remain unanswered. For example, the defense mechanism of M2e-containing vaccines has not been fully clarified [<xref ref-type="bibr" rid="CR71">71</xref>]. Since anti-M2e antibodies were discovered [<xref ref-type="bibr" rid="CR140">140</xref>], it has been believed that they are the main mechanism of the protective action that has been repeatedly shown in various animal models [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Importantly, several groups have noted that M2e-based influenza vaccines induced a long-lasting M2e-specific antibody response [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. The presence of antibody 14C2 reduces the expression level of viral protein M2 [<xref ref-type="bibr" rid="CR45">45</xref>], thereby indirectly affecting the formation of new viral particles. However, it has been shown that influenza viruses that have mutations in the C-terminal region of M2 and the N-terminal region of M1 (even one amino acid substitution could be sufficient, for example, Pro10His, Val31Ile or Ala41Val) are resistant to the action of antibody 14C2 [<xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR142">142</xref>].</p><p id="Par51">Although the anti-M2e antibody are not neutralizing [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR89">89</xref>], their significant protective effect was demonstrated in multiple experiments, including studies on passive transfer of M2e immune serum or anti-M2e monoclonal antibodies [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR121">121</xref>]. In addition, Eliasson et al. [<xref ref-type="bibr" rid="CR26">26</xref>] showed that B cell-deficient mice are very poorly protected by a mucosal M2e-based vaccine even though these mice mount a considerable CD4 T cell response against M2e. In 2011, El Bakkouri et al. [<xref ref-type="bibr" rid="CR24">24</xref>] demonstrated the crucial role of Fc gamma receptors (Fc&#x003b3;R) in the in vivo protection afforded by M2e-specific IgG isotypes. In this study, wild-type and FcR &#x003b3;<sup>&#x02212;/&#x02212;</sup> BALB/c mice were passively immunized with anti-M2e immune serum, followed by lethal challenge with a mouse-adapted virus. Despite similar distribution of anti-M2e IgG titers and antibody isotype in both mouse strains, the FcR &#x003b3;<sup>&#x02212;/&#x02212;</sup> mice were significantly less protected than wild-type animals. Further experiments demonstrated that the activating receptor Fc&#x003b3;RIII associated with the common &#x003b3;-chain is required for anti-M2e IgG1 isotype-mediated in vivo immune protection [<xref ref-type="bibr" rid="CR24">24</xref>]. Similar results were yielded in study by Lee et al. [<xref ref-type="bibr" rid="CR72">72</xref>]: although the wild-type mice and FcR &#x003b3;<sup>&#x02212;/&#x02212;</sup> genotype mice had similar levels of antibodies (IgG1 and IgG2a) after immunization with M2e5x virus-like particles (VLP), the vaccine was significantly less protective in mice without an FcR &#x003b3;-chain than in wild-type mice. Van den Hoecke et al. [<xref ref-type="bibr" rid="CR124">124</xref>] showed that protection against influenza virus with different IgG antibody subclasses requires different FcR subtypes: protection with IgG1 requires Fc&#x003b3;RIII, while IgG2a requires all three activating Fc&#x003b3;Rs.</p><p id="Par52">It is known that M2 protein is expressed abundantly on the surface of infected cells, whereas only a few molecules are incorporated into the virion [<xref ref-type="bibr" rid="CR140">140</xref>], therefore anti-M2e IgG antibody provide protection by interacting with virus-infected cells and triggering immune effector cell activation through its Fc region, resulting in killing and/or phagocytosis of the infected cells [<xref ref-type="bibr" rid="CR24">24</xref>]. Many studies attempted to identify the effector cells which are responsible for elimination of M2-expressing cells in the presence of anti-M2e IgGs. Controversial results were yielded with respect to the formation of natural killer (NK)-mediated ADCC in response to immunization with M2e-containing vaccines. A number of studies have shown that the ADCC mechanism has an essential role of [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR128">128</xref>], whereas experiments with peptide-specific monoclonal antibodies have refuted this [<xref ref-type="bibr" rid="CR32">32</xref>]. These studies [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR128">128</xref>] looked at the effect of NK-mediated ADCC during passive immunization, which introduces additional difficulties in identifying the true mechanism of protection. Using a conditional cell depletion protocol, El Bakkouri et al. [<xref ref-type="bibr" rid="CR24">24</xref>] demonstrated that alveolar macrophages (AM) play a critical role in the protection mediated by anti-M2e IgG antibody. These results are of particular interest because AM are resident in the lung and are considered one the first immune cells to interfere with respiratory pathogens in the airways. The contribution of these components of the immune system alone is not sufficient for a complete defense, but it can influence innate immunity and the first stages of the adaptive immune response [<xref ref-type="bibr" rid="CR110">110</xref>]. The activation of the complement system as a result of viral elimination after immunization with M2e-containing vaccines also raises questions [<xref ref-type="bibr" rid="CR71">71</xref>]. The complement system can bind to influenza virions in the presence of virus-specific antibodies [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. A study by Wang et al. [<xref ref-type="bibr" rid="CR128">128</xref>] showed the importance of the C3 complement system in reducing viral titer in the lungs of mice after challenge, although Jegerlehner et al. [<xref ref-type="bibr" rid="CR53">53</xref>] found that the system does not play a significant role in protection.</p><p id="Par53">Various studies have also demonstrated the importance of the M2e-specific CD4+ and CD8+ responses [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. CD8 T cells are known to kill target cells via perforin and FasL-mediated cytotoxicity pathways, thereby providing viral clearance [<xref ref-type="bibr" rid="CR120">120</xref>], while CD4 cells influence the production of IFN-&#x003b3;, which is involved in reducing viral titer [<xref ref-type="bibr" rid="CR6">6</xref>]. Experiments on T-cell depletion showed the joint importance of CD4+ and CD8+ T cells in heterosubtypic cross-protection [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR119">119</xref>], however different studies yielded discrepant results in M2e-specific T-cell responses, most probably due to the differences in immunization protocols, vaccine platforms and adjuvants, strains of animals, and routes of immunization [<xref ref-type="bibr" rid="CR71">71</xref>]. A study by Eliasson et al. [<xref ref-type="bibr" rid="CR26">26</xref>] demonstrated a critical role of M2e-specific lung-resident memory CD4, but not CD8, T cells induced by mucosal CTA1-3M2e-DD vaccine in protecting mice against a lethal influenza virus infection. Importantly, these CD4 T-cell responses were long-lasting, protecting animals even 12&#x02009;months after vaccination [<xref ref-type="bibr" rid="CR26">26</xref>]. In the study by Lee et al., the M2e5x VLP-immunized FcR &#x003b3;<sup>&#x02212;/&#x02212;</sup> mice recovered more quickly after viral exposure than na&#x000ef;ve FcR &#x003b3;<sup>&#x02212;/&#x02212;</sup> mice, most probably due to the prevalence of IFN-&#x003b3;-producing CD4 and CD8 T cells in the lungs of immunized FcR &#x003b3;<sup>&#x02212;/&#x02212;</sup> mice [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par54">In summary, no complete defense mechanism valid for all M2e-containing vaccines has been found so far. All of the contradictory data mentioned can be explained by unaccounted mechanisms in the formation of protection or by the additional influence of the M2e carrier (studies with contradictory results used different types of carriers). Another factor may be the lack of a unified methodology. However, all researchers agree that the response to M2e-containing vaccines involves many key parts of the immune system, which can have a significant protective effect.</p></sec><sec id="Sec5"><title>Possible modifications of M2e</title><p id="Par55">Most studies aimed at preparing a universal M2e-based influenza vaccine have used the whole M2 ectodomain (a.a. 2&#x02013;24). However, truncated forms of M2e (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) can be used to induce an immune response to important areas of M2e, reduce the cost of vaccine production and allow the use of new vectors that have a small capacity. For example, there are a number of antibodies (14C2, 3F12, 8C6, 1B12, Z3G1) [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR140">140</xref>] that recognize only a fraction of the total M2e, and that find wide application in practice.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Antigenic variants of M2e fragments</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Major feature</th><th>2</th><th>3</th><th>4</th><th>5</th><th>6</th><th>7</th><th>8</th><th>9</th><th>10</th><th>11</th><th>12</th><th>13</th><th>14</th><th>15</th><th>16</th><th>17</th><th>18</th><th>19</th><th>20</th><th>21</th><th>22</th><th>23</th><th>24</th><th>Reference</th></tr></thead><tbody><tr><td>The most conservative part of M2e</td><td>S</td><td>L</td><td>L</td><td>T</td><td>E</td><td>V</td><td>E</td><td>T</td><td>P</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>[<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td>TCN-031 and TCN-032 antibodies recognition site</td><td>S</td><td>L</td><td>L</td><td>T</td><td>E</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>[<xref ref-type="bibr" rid="CR37">37</xref>]</td></tr><tr><td>O19 antibody recognition site</td><td>S</td><td>L</td><td>L</td><td>T</td><td>E</td><td>V</td><td>E</td><td>T</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td valign="middle" rowspan="3">[<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td>L18 antibody recognition site</td><td/><td/><td>L</td><td>T</td><td>E</td><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td>N</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>S1 antibody recognition site</td><td/><td/><td/><td/><td/><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td>N</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Influenza A and B virus neutralizing activity in vitro</td><td>S</td><td>L</td><td>L</td><td>T</td><td>E</td><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>[<xref ref-type="bibr" rid="CR77">77</xref>]</td></tr><tr><td>Presence of B-cell epitope and 14C2 antibody recognition site</td><td/><td/><td/><td/><td>E</td><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td>N</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>[<xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td><p>High affinity of binding with HLA-A2;</p><p>presence of T-cell epitope</p></td><td/><td>L</td><td>L</td><td>T</td><td>E</td><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>[<xref ref-type="bibr" rid="CR36">36</xref>]</td></tr><tr><td>Potential epitope</td><td/><td/><td/><td/><td/><td/><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td valign="middle" rowspan="3">[<xref ref-type="bibr" rid="CR94">94</xref>]</td></tr><tr><td>Presence of CTL-cell epitopes</td><td>S</td><td>L</td><td>L</td><td>T</td><td>E</td><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td>N</td><td>E</td><td>W</td><td>G</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Some critical residues for T-helpers</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>C</td><td>R</td><td>C</td><td>N</td><td>D</td><td>S</td><td>S</td><td>D</td></tr><tr><td>Recognition of HLA-B44-restricted CD8+ CTL line 124</td><td/><td/><td/><td/><td/><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td>N</td><td>E</td><td>W</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td>MHC class II H-2d-restricted epitope</td><td/><td/><td/><td/><td/><td/><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td>N</td><td>E</td><td>W</td><td>G</td><td>S</td><td>R</td><td/><td/><td/><td/><td/><td/><td>[<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td>L66 antibody recognition site</td><td>S</td><td>L</td><td>L</td><td>T</td><td>E</td><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td>N</td><td>E</td><td>W</td><td>G</td><td/><td/><td/><td/><td/><td/><td/><td/><td valign="middle" rowspan="5">[<xref ref-type="bibr" rid="CR128">128</xref>]</td></tr><tr><td>N547 antibody recognition site</td><td/><td>L</td><td>L</td><td>T</td><td>E</td><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td>N</td><td>E</td><td>W</td><td>G</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Z3G1 antibody recognition site</td><td/><td>L</td><td>L</td><td>T</td><td>E</td><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>C40G1 antibody recognition site</td><td/><td/><td/><td/><td/><td/><td/><td>T</td><td>P</td><td>I</td><td>R</td><td>N</td><td>E</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>14C2 antibody recognition site</td><td/><td/><td/><td/><td>E</td><td>V</td><td>E</td><td>T</td><td>P</td><td>I</td><td>R</td><td>N</td><td>E</td><td>W</td><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr></tbody></table></table-wrap></p><p id="Par56">Induction of all kinds of anti-M2e antibodies is required for maximum protection of M2e-containing vaccines. However, these antibodies have different protective characteristics, and an optimum universal influenza vaccine may use only some of the M2e sites that induce the most effective antibodies (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par57">Fu et al. [<xref ref-type="bibr" rid="CR32">32</xref>] compared different anti-M2e antibodies, and showed that the protective properties of L18 antibody (which recognizes the M2e 4&#x02013;13 site) were superior to those of O19 (which recognizes the M2e 2&#x02013;9 site), while S1 (recognizes the M2e 7&#x02013;13 site) did not protect mice against lethal influenza A virus challenge. Data from other groups indicate that the M2e 4&#x02013;13 region contains a B-cell epitope and a sequence recognized by the 14C2 antibody (M2e 6&#x02013;13) [<xref ref-type="bibr" rid="CR79">79</xref>], as well as an additional potential epitope (M2e 8&#x02013;12) [<xref ref-type="bibr" rid="CR94">94</xref>].</p><p id="Par58">It is worth noting that, when shortened forms of the ectodomain M2 are used, and with regard to various defense mechanisms, the carrier of M2e epitopes plays an important role in immunogenicity. For example, immunization with a shortened form of M2e (2&#x02013;16 amino acid residues) along with Freund&#x02019;s adjuvant did not lead to the formation of a high level of anti-M2e antibodies [<xref ref-type="bibr" rid="CR94">94</xref>], unlike when phage f88 was used as a carrier of M2e antigen [<xref ref-type="bibr" rid="CR20">20</xref>]. It was concluded that a shortened form of M2e will produce a high level of anti-M2e antibodies only with a support system capable of inducing a T-cell response. This study also revealed the presence in M2e (17&#x02013;24 a.a.) of amino acids important for the formation of a T-cell response.</p></sec><sec id="Sec6"><title>Development of M2e-based vaccines</title><p id="Par59">The inhibition of replication of some influenza A strains by 14C2 antibody [<xref ref-type="bibr" rid="CR140">140</xref>] merited further study since the extracellular part of the M2 protein is very conservative compared with HA and NA, and the cross-protective effect can be directed precisely at M2e. Study of the protective properties of 14C2 in BALB/c mice showed that it significantly reduced the replication of influenza A (but not influenza B) virus in lung tissue. This prompted the suggestion that the higher immunity of adults who have previously had influenza A infection compared with children is provided by the presence of M2e antibodies [<xref ref-type="bibr" rid="CR121">121</xref>]. However, subsequent studies have shown that M2e itself is a weak immunogen and that only about half the people infected with influenza A virus are able to produce anti-M2e antibodies [<xref ref-type="bibr" rid="CR143">143</xref>]. There is no reliable evidence that such a low concentration of antibodies plays any protective role [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR143">143</xref>]. It has also been suggested that the introduction of M2e epitopes into the influenza vaccine will have a priming effect on the production of antibodies before subsequent influenza A virus infection [<xref ref-type="bibr" rid="CR143">143</xref>].</p><p id="Par60">Despite numerous reports of the low immunogenicity of M2e because of its small size, small number of copies in the virion, and the possible shielding effect of larger surface proteins of influenza A virus [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR140">140</xref>], it has been shown that immunization with free synthetic M2e peptide together with an adjuvant can produce high titers of anti-M2e antibodies that protect mice from lethal influenza challenge [<xref ref-type="bibr" rid="CR138">138</xref>]. However, most attempts to create a universal M2e-based influenza vaccine have used different carriers. One of the first studies used a recombinant baculovirus containing M2 from influenza virus A/Ann Arbor/6/60 (Bac-AM2), to infect the <italic>Spodoptera frugipedra</italic> (Sf9) cell line. 14C2 antibody detection revealed the presence of M2 on the surface of infected cells. This allowed the use of Sf9 lysates infected with Bac-AM2 as a source of antigen to study the antibody response to M2 in people previously infected with influenza A virus [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par61">One of the first prototypes of a universal influenza vaccine used hepatitis B core protein combined with the M2e peptide (M2HBc) as a carrier. In this design, the natural position of the N-terminal region of M2, located in the extracellular space, was simulated. Immunization of BALB/c mice with M2HBc resulted in a high level of protection against the lethal dose of influenza A virus, and led to the formation of anti-M2e antibodies, which were shown to be effective in passive immunization experiments [<xref ref-type="bibr" rid="CR88">88</xref>]. Later various liposomal carriers [<xref ref-type="bibr" rid="CR1">1</xref>], tobacco mosaic virus surface protein [<xref ref-type="bibr" rid="CR96">96</xref>], and rotavirus NSP4 [<xref ref-type="bibr" rid="CR3">3</xref>] were used to induce anti-M2e antibodies. Another carrier used was the GCN4 protein, which is a eukaryotic transcriptional protein activator. The use of M2e-tGCN4 resulted in significant production of M2e-specific antibodies, which protected vaccinated mice from a lethal dose of mouse-adapted influenza virus [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par62">The most effective and cost-effective method is the creation of recombinant virus-like particles (VLPs), on the surface of which M2e would be represented [<xref ref-type="bibr" rid="CR19">19</xref>]. Because M2 is a homotetramer consisting of two subunits linked by a disulfide bond, held together by covalent interactions [<xref ref-type="bibr" rid="CR88">88</xref>], it has been suggested that M2e could also be used as a tetramer in the creation of recombinant constructs. In this approach, M2e will form a compactly folded protein, thereby ensuring the correct geometry of the virus particles. In addition, there are confirmations of the creation of VLPs consisting of five M2e tandem repeats (M2e5x). The intramuscular administration of M2e5x protected mice from influenza A viruses of different serotypes [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par63">There are data on the highly conservative nature of Cys17 and Cys19 residues, although, in many studies, these residues were replaced by Ser17 and Ser19, respectively, in order to avoid protein aggregation due to the formation of disulfide bonds between M2e sites. Such substitutions are widely used because it has been shown that Cys17 and Cys19 residues do not affect the expression of M2e [<xref ref-type="bibr" rid="CR44">44</xref>], and the double substitution does not affect the immunogenic properties of M2e epitopes [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par64">It is interesting to note that in the vast majority of successful M2e vaccine studies mouse models were used, while only a few studies were conducted on other animals (pigs, ferrets, monkeys, dogs), where protection against challenge, if studied, was modest at best. One possible explanation for such diverse results is that mice of various inbred (including knockout and knock-in) strains are readily available at relatively low cost, whereas larger animals are more expensive and genetically outbred, resulting in significant host response variability. Even ferrets within commercial populations have distinct patterns of T-cell reactivity as a result of the heterogeneity at the MHC locus [<xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, primary structure, cellular specificity and binding properties of Fc receptors can vary considerably among different mammalian species [<xref ref-type="bibr" rid="CR54">54</xref>]. For example, a recent study found that pig Fc receptors do not bind human IgG1, which limits the use of this animal model to study human broadly protective monoclonal antibodies [<xref ref-type="bibr" rid="CR85">85</xref>].</p><p id="Par65">In summary, there are many ways to increase the immunogenicity of M2e. The most significant findings from preclinical studies of these universal vaccine prototypes are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. However, their further use in clinical practice is limited by the lack of knowledge about the safety of the vectors for humans. Currently, the search for new carriers continues, in order to increase the immunogenicity of M2e, while new immunization strategies are also being sought, such as priming with live attenuated influenza virus, and boosting with M2e VLP [<xref ref-type="bibr" rid="CR73">73</xref>].
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Some examples of M2e-based vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Carrier</th><th>Animals</th><th>Immunization route*</th><th>Main results</th><th>Reference</th></tr></thead><tbody><tr><td rowspan="2">Hepatitis B virus core protein</td><td>Mice</td><td>IP<sup>+</sup> or IN</td><td>3 immunizations at 3-week intervals with 5, 10, or 50&#x02009;&#x003bc;g led to the formation of M2e-antibodies in mice. Groups immunized with 10&#x02009;&#x003bc;g IP and IN in subsequent vaccination studies were protected after challenge with 5 LD<sub>50</sub> of A/PR/8/34 (H1N1) and A/Victoria/3/75 (H3N2). The significant role of M2e antibodies in passive transfer experiments was shown.</td><td>[<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td>Mice</td><td>IM<sup>+</sup></td><td>3 immunizations at 2-week intervals with 50&#x02009;&#x003bc;g induced high levels of M2e-antibodies. Challenge with 5 LD<sub>50</sub> of different heterologous viruses showed high degree of protection.</td><td>[<xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td>Modified form of the leucine zipper of the yeast transcription factor GCN4</td><td>Mice</td><td>IP<sup>+</sup> or IN<sup>+</sup></td><td>3 immunizations with 10&#x02009;&#x003bc;g doses led to the formation of specific IgG1 and IgG2a M2e antibodies. The tetrameric M2e-tGCN4 vaccine induced M2e-specific IgG antibody that recognized natural M2 ectodomain. Immunized mice were fully protected against challenge with 4 LD<sub>50</sub> X47.</td><td>[<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td>Prime with M2-DNA and boost with recombinant adenovirus expressing M2</td><td>Mice</td><td>IM</td><td>2 immunizations (50&#x02009;&#x003bc;g each) led to the enhanced antibody response. Challenge with LD<sub>50</sub> of A/PR/8/34 (H1N1) and 10 LD<sub>50</sub> of A/FM/1/47-MA (H1N1) and LD<sub>50</sub> A/Thailand/SP-83/2004 (H5N1) showed the significant cross-protection of the vaccine. The important protective role of CD4&#x02009;+&#x02009;and CD8&#x02009;+&#x02009;cells was also shown.</td><td>[<xref ref-type="bibr" rid="CR119">119</xref>]</td></tr><tr><td>T7 bacteriophage nanoparticles</td><td>Mice</td><td>SC<sup>+</sup></td><td>3 immunizations (10<sup>9</sup> PFU each) led to the formation of IgG1 and IgG2a M2e-antibodies, as well as a T-cell response. Challenge with 4 LD<sub>50</sub> of A/PR/8/34 (H1N1) and X47 showed a high degree of protection.</td><td>[<xref ref-type="bibr" rid="CR38">38</xref>]</td></tr><tr><td>Rotavirus fragment NSP4<sub>98&#x02013;135</sub></td><td>Mice</td><td>SC<sup>+</sup></td><td>3 immunizations (10&#x02009;&#x003bc;g each) with a chimeric protein resulted in the formation of an increased level of antibodies compared with immunization with M2e peptides. The formation of IgG1 M2e antibodies and to a lesser extent IgG2a was induced. Challenge using 3 LD<sub>50</sub> of A/PR/8/34 (H1N1) or A/equine/London/72 (H7N7) did not reveal significant differences between the chimeric and peptide vaccine, however lung virus titers 3 d.p.i. were significantly lower in the M2e-NSP4 group.</td><td>[<xref ref-type="bibr" rid="CR3">3</xref>]</td></tr><tr><td rowspan="3">Keyhole limpet hemocyanin (KLH) or <italic>Neisseria meningitides</italic> outer membrane protein complex (OMPC)</td><td>Mice</td><td>SC or IM<sup>+</sup></td><td>3 immunizations (20&#x02009;&#x003bc;g each) at 4-week intervals led to the formation of high levels of antibodies with cross-reactivity. Challenge with LD<sub>90</sub> of A/Hong Kong/68xPR8 reassortant resulted in complete survival and lower weight loss in vaccinated mice compared with controls.</td><td valign="middle" rowspan="3">[<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td>Ferrets</td><td>IM<sup>+</sup></td><td>3 immunizations (100&#x02009;&#x003bc;g each) at 4-week intervals showed that the OMPC-based vaccine was more immunogenic than the KHL-based vaccine. Challenge with 100 TCID<sub>50</sub> A/PR/8/34 (H1N1) revealed significantly lower replication of the challenge virus in the nasal turbinates and lungs.</td></tr><tr><td>Rhesus monkeys</td><td>IM<sup>+</sup></td><td>3 immunizations (10&#x02009;&#x003bc;g each) during 25&#x02009;weeks (immunization on 0, 8, and 25&#x02009;weeks) with an OMPC-based vaccine led to the formation of an increased level of M2e antibodies. Sera were examined after challenge with A/Hong Kong/68xPR8 after passive transfer immunization of mice, and protective efficacy was shown.</td></tr><tr><td><italic>Brucella abortus</italic> lumazine synthase protein (BLS)</td><td>Mice</td><td>SC, SC<sup>+</sup>, IM, IM<sup>+</sup>, IN, IN<sup>+</sup></td><td>3 immunizations (10&#x02009;&#x003bc;g each) using various routes at 3-week intervals led to the formation of IgG1 and IgG2a M2e-antibodies in different ratios. SC+ immunization produced the highest level of antibodies and was chosen for further study. Challenge with 5 LD<sub>50</sub> of A/PR/8/34 (H1N1) showed the protective efficacy of the vaccine.</td><td>[<xref ref-type="bibr" rid="CR2">2</xref>]</td></tr><tr><td rowspan="2">Malva mosaic virus nanoparticles</td><td>Mice</td><td>SC<sup>+</sup></td><td>2 immunizations (20&#x02009;&#x003bc;g each) at a 2-week interval led to the formation of IgG1 and IgG2a M2e-antibodies, whereas immunization with M2e peptides was not immunogenic. Significantly lower replication of the challenge virus in nasal turbinates and lungs was shown after challenge with A/WSN/1933 (H1N1).</td><td valign="middle" rowspan="2">[<xref ref-type="bibr" rid="CR70">70</xref>]</td></tr><tr><td>Dogs</td><td>IM<sup>+</sup></td><td>3 immunizations (80&#x02009;&#x003bc;g each) at 3-week intervals led to the formation of cross-reactive M2e-antibodies and revealed the need for adjuvant. Challenge was not performed.</td></tr><tr><td>H1N1 HA DNA</td><td>Mice</td><td>IM<sup>+</sup></td><td>2 immunizations (0.2&#x02009;&#x003bc;g each) at a 3-week interval led to the formation of cross-reactive M2e-antibodies. High protection of immunized mice was shown against challenge with 5 LD<sub>50</sub> of A/Aquatic Bird/Korea/W81/2005. In addition, HA-specific CD8+ and M2e-specific T cell responses were elicited</td><td>[<xref ref-type="bibr" rid="CR92">92</xref>]</td></tr><tr><td rowspan="3"><italic>Salmonella typhimurium</italic> flagellin</td><td>Mice</td><td>SC</td><td>3 immunizations (6&#x02009;&#x003bc;g each) at 3-week intervals led to the formation of a high level of M2e-antibodies. Full protection of vaccinated mice was shown against challenge with 10 LD<sub>50</sub> of A/Aichi/2/68 (H3N2).</td><td>[<xref ref-type="bibr" rid="CR113">113</xref>]</td></tr><tr><td>Mice</td><td>SC or IN</td><td>2 immunizations (3&#x02009;&#x003bc;g each) at a 2-week interval led to the formation of a higher rate of M2e-antibodies than immunization with M2e-peptides. There was no decline in the following 10&#x02009;months. High protection of immunized mice was shown against challenge with LD<sub>90</sub> of A/PR/8/34 (H1N1).</td><td valign="middle" rowspan="2">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td>Rabbits</td><td>IM</td><td>2 immunizations (15&#x02009;&#x003bc;g each) at a 3-week interval led to the formation of M2e-antibodies.</td></tr><tr><td>Multiple antigenic peptide</td><td>Mice</td><td>SC<sup>+</sup></td><td>Single immunization led to the formation of high levels of M2e antibodies, which insignificantly declined in the following 6&#x02009;months. 2 immunizations led to significant clearance of virus 3&#x02009;days after challenge with 10 LD<sub>50</sub> A/Beijing/501/09 and protected against weight loss.</td><td>[<xref ref-type="bibr" rid="CR141">141</xref>]</td></tr><tr><td>DNA expressing fusion M2e-NP protein</td><td>Pigs</td><td>SC<sup>+</sup></td><td>3 immunizations (200&#x02009;&#x003bc;g each) at 3-week intervals did not protect animals after challenge with 10<sup>8</sup> TCID<sub>50</sub> of A/Sw/Best/96 (H1N1) but led to more serious signs of disease compared with the control group.</td><td>[<xref ref-type="bibr" rid="CR41">41</xref>]</td></tr><tr><td>Lipopeptides</td><td>Mice</td><td>SC</td><td>2 immunizations (20&#x02009;nmol each) at a 2-week interval with shortened form of M2e (a.a. 2&#x02013;16) led to the same level of M2e antibody production as immunization with full-length M2e (a.a. 2&#x02013;24), and led to lower viral titers in lungs and nasal turbinates after challenge with 10<sup>4.5</sup> PFU of A/Memphis/1/71xA/Bellamy/42 (H3N1) virus.</td><td>[<xref ref-type="bibr" rid="CR94">94</xref>]</td></tr><tr><td rowspan="2">Keyhole limpet haemocyanin (KLH with full length M2e (M2e-KLH) and M2e<sub>2&#x02013;10</sub> (SP1-KHL)</td><td>Mice</td><td>IP<sup>+</sup></td><td>3 immunizations at 3-week intervals led to the formation of M2e-antibodies for both vaccines. Vaccinated groups were more protected than the control group against challenge with 4 LD<sub>50</sub> of A/PR/8/34 (H1N1). M2e-KLH was more immunogenic and protective than SP1-KHL.</td><td valign="middle" rowspan="2">[<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td>Rabbits</td><td>n/m</td><td>3 immunizations at 3-week intervals showed greater immunogenicity of SP1-KHL. Serum from immunized rabbits provided protection in a mice passive transfer study against challenge with 4 LD<sub>50</sub> of A/PR/8/34 (H1N1). SP1-KHL was also more immunogenic in outbred New Zealand white rabbits than in inbred BALB/c mice.</td></tr><tr><td>VLP</td><td>Mice</td><td>IM</td><td>2 immunizations at a 4-week interval led to the formation of M2e-antibodies, and protected mice against challenge with 4 LD<sub>50</sub> of A/Philippines/2/82(H3N2) 4&#x02009;weeks and 8&#x02009;months after boost.</td><td>[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td>M13 phage</td><td>SPF chickens</td><td>IM<sup>+</sup> (1st), IM (2nd)</td><td>2 immunizations with the hybrid phage expressing shortened form of M2e (a.a. 2&#x02013;9) at a dose of 1&#x02009;&#x000d7;&#x02009;10<sup>10</sup> phage/200&#x02009;&#x003bc;L produced specific antibodies against M2e (2&#x02013;9) in broiler chickens.</td><td>[<xref ref-type="bibr" rid="CR80">80</xref>]</td></tr><tr><td>CTA1-DD</td><td>Mice</td><td>IN</td><td>2 immunizations at 3-week intervals induced strong M2e-specific serum antibody response and stimulated significant anti-M2e IgA antibody titers in bronchial lavage. Vaccination provided strong protective immunity against challenge with 4 LD<sub>50</sub> of X47 virus.</td><td>[<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td>8C6 and 1B12 antibodies (recognize M2e<sub>6&#x02013;13</sub>)</td><td>Mice</td><td>IP (passive transfer)</td><td>Passive transfer with 8C6 and 1B12 led to the formation of a high level of M2e antibodies and 75% protection of vaccinated mice against challenge with 5 LD<sub>50</sub> of A/PR/8/34 (H1N1), compared with 0% protection in control group.</td><td>[<xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td>M2e-specific IgG2a MAb65</td><td>Mice</td><td>IP (passive transfer)</td><td>Passive immunization reduced transmission of A/Udorn/72 (H3N2) and A/Hong Kong/68 (H3N2) challenge viruses and led to lower viral titer in lungs and nasal turbinates.</td><td>[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr></tbody></table><table-wrap-foot><p>* IP, intraperitoneal: IN, intranasal; SC, subcutaneous; IM, intramuscular;&#x000a0;n/m, not mentioned; <sup>+</sup>, with adjuvant</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec7"><title>Clinical studies of M2e-based influenza vaccines</title><p id="Par66">M2e-based vaccines are not available commercially, but some are currently undergoing clinical trials (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). For example, the ACAM-FLU-A vaccine, an M2e-HBc fusion protein, based on an idea by Neirynck [<xref ref-type="bibr" rid="CR88">88</xref>], has already passed the first phase of double-blind placebo-controlled clinical trial (NCT00819013, Sanofi). Intramuscular administration of ACAM-FLU-A promoted the formation of anti-M2e antibodies in blood sera in 90% of cases and was well tolerated when given alone or with aluminum hydroxide or QS-21 Stimulon adjuvant (<ext-link ext-link-type="uri" xlink:href="http://www.biocentury.com/bc-week-review/clinical-results/2008-01-07/acam-flu-phase-i-data">www.biocentury.com/bc-week-review/clinical-results/2008-01-07/acam-flu-phase-i-data</ext-link>). However, there has been no further progress with this vaccine since then, probably because of the rapid decline in M2e-specific antibody over time [<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov"><italic>clinicaltrials.gov</italic></ext-link> NCT00819013]. A similar recombinant protein HBc-based prototype universal influenza vaccine, &#x0201c;Uniflu&#x0201d;, is currently being evaluated in a single-site, randomized, double-blind, placebo-controlled study in Saint Petersburg, Russia [<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov"><italic>clinicaltrials.gov</italic></ext-link> NCT03789539]. The vaccine contains four copies of human M2e fused within the immunodominant loop of the HBc antigen [<xref ref-type="bibr" rid="CR122">122</xref>]. This study involves 54 healthy adult subjects 18&#x02013;60&#x02009;years, and the vaccine is administered intramuscularly in two different doses (20 and 40&#x02009;&#x003bc;g) twice at a 3-week interval. The results of the trial are anticipated in the near future.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Clinical trials of M2-based vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Company (country)</th><th>Phase</th><th>Year</th><th><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">Clinicaltrials.gov</ext-link> identifier</th><th>Available results</th></tr></thead><tbody><tr><td>VaxInnate (USA)</td><td>I</td><td>2007&#x02013;2008</td><td>NCT00603811</td><td>No</td></tr><tr><td>Sanofi (France)</td><td>I</td><td>2007&#x02013;2009</td><td>NCT00819013</td><td>Yes</td></tr><tr><td>VaxInnate (USA)</td><td>I</td><td>2009</td><td>NCT00921206</td><td>Yes [<xref ref-type="bibr" rid="CR123">123</xref>]</td></tr><tr><td>VaxInnate (USA)</td><td>II</td><td>2009&#x02013;2011</td><td>NCT00921947</td><td>Yes</td></tr><tr><td>VaxInnate (USA)</td><td>I/ II</td><td>2009&#x02013;2010</td><td>NCT00921973</td><td>Yes [<xref ref-type="bibr" rid="CR117">117</xref>]</td></tr><tr><td>Imutex Limited (United Kingdom)</td><td>I</td><td>2010</td><td>NCT01181336</td><td>No</td></tr><tr><td>GeneOne Life Science (Republic of Korea)</td><td>I</td><td>2010&#x02013;2012</td><td>NCT01184976</td><td>No</td></tr><tr><td rowspan="2">Theraclone Sciences (USA)</td><td>I</td><td>2012</td><td>NCT01390025</td><td rowspan="2">Yes [<xref ref-type="bibr" rid="CR99">99</xref>]</td></tr><tr><td>II</td><td>2012</td><td>NCT01719874</td></tr><tr><td>VA Pharma LLC (Russian Federation)</td><td>I</td><td>2018</td><td>NCT03789539</td><td>No</td></tr></tbody></table></table-wrap></p><p id="Par67">Another influenza vaccine based on the use of flagellin to increase the immunogenicity of M2e [<xref ref-type="bibr" rid="CR46">46</xref>] was shown to be safe in a phase I clinical trial after intramuscular administration in doses of 0.3 and 1.0&#x02009;&#x003bc;g. However, administration in doses of 3.0&#x02009;&#x003bc;g or 10.0&#x02009;&#x003bc;g was accompanied by undesirable symptoms (fever, diarrhea, fatigue, headache and muscle pain), although this vaccine demonstrated high immunogenicity (NCT00921206, VaxInnate) [<xref ref-type="bibr" rid="CR123">123</xref>]. The phase II trial of this vaccine ended in 2011 (NCT00921947, VaxInnate), but the test results are not yet available.</p><p id="Par68">One more vaccine, containing M2 peptides and various conservative CTL epitopes [<xref ref-type="bibr" rid="CR114">114</xref>], also passed the first phase of clinical trials (NCT01181336, Imutex Limited). However, this vaccine stimulates cellular immunity and is HLA-specific, which may be a reason for its narrow focus. Also, the cellular immune response is slower than the humoral response, and in the event of a pandemic, it would not effectively prevent infection [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par69">Clinical trials to study the effect of the presence of additional M2e antigens in the trivalent vaccine have shown that, in the case of a weak response to the main vaccine, the M2e component can significantly enhance the immune response [<xref ref-type="bibr" rid="CR117">117</xref>]. Thus, additional M2e epitopes will be able to have a &#x0201c;safety net&#x0201d; function when such vaccines are introduced into wide practice.</p><p id="Par70">The TCN-032 antibody passed phase I of clinical trials. Volunteers were given a single dose of TCN-032 intravenously (1, 3, 10, 20, or 40&#x02009;mg/kg of body weight), and no severe events related to the study drug were observed. A phase II clinical trial showed that non-neutralizing antibody TCN-032 has a therapeutic effect, as parenteral administration provided immediate immunity and therapeutic benefit in influenza A infection [<xref ref-type="bibr" rid="CR99">99</xref>].</p><p id="Par71">Overall, many prototype universal influenza vaccines contain an increased number of M2e epitopes. The data suggest that there is potential to use such vaccines, but that they need to be improved, in order to overcome the existing shortcomings.</p></sec><sec id="Sec8"><title>Conclusions</title><p id="Par72">Vaccination is the safest and most effective way to prevent the spread of influenza. However, seasonal vaccination is ineffective against pandemic influenza viruses, as it is often antigenically different from the pandemic virus, and it takes an average of six months to prepare a new vaccine candidate for deployment. The development of a universal influenza vaccine, which would have a long and broad spectrum of action, is an urgent issue of practical public health.</p><p id="Par73">Currently, new universal influenza vaccines are being developed using various strategies, but none of these vaccines has been licensed so far. The development of a new universal influenza vaccine will both avoid the need for annual updates to the composition of seasonal vaccines, and reduce the risk of public health disaster in the event of a new pandemic. However, it is not yet clear whether such vaccines will induce long-lasting protection. It is also unknown how the effects of influenza viruses and previous vaccinations will affect the performance of new vaccines [<xref ref-type="bibr" rid="CR91">91</xref>].</p><p id="Par74">Ideally, a universal influenza vaccine should induce both a humoral (antibodies) and a T-cell immune response to conservative epitopes of the influenza virus. M2e and HA stalk domain are the most widely used viral targets for a universal influenza vaccine design due to their conserved nature and the proven ability of their specific antibody to protect against heterologous viral infections. Many vaccination strategies have been explored to elicit potent antibody responses against these naturally weak immunogens. The vaccine-induced anti-HA stalk antibodies target either group 1 or group 2 HAs, with limited cross-reactivity between the two HA groups, suggesting that a cHA-based universal influenza vaccine has to include three components: a group 1 HA, a group 2 HA, and an influenza B stalk-based antigen [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. In contrast, a properly designed M2e-based vaccine should cover all influenza A virus subtypes circulating in both human and animal reservoirs. Since it is not possible to predict which virus will cause the next pandemic, we recommend that four different M2e consensus sequences be included in the new M2e-based vaccines to maximize cross-reactivity of the M2e-targeted antibody against all circulating influenza A viruses (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Licensing of a new M2e-based vaccine is challenging due to the lack of clearly defined correlates of protections of such vaccines for humans. In addition, the M2e-specific protection is of lower potency compared to HA-targeted neutralizing immunity, therefore the problem of proving non-inferiority over existing influenza vaccines remains to be solved. Nevertheless, the conserved M2 ectodomains can be used as a supplement to overcome strain specificity and improve long-term cross-protection of currently licensed seasonal influenza vaccines [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR87">87</xref>].</p><p id="Par75">It is worth mentioning that it is possible that a new antigenic drift, different from that observed in wild strains, will start to act on conservative epitopes, which will make it necessary to periodically update the composition of any universal vaccine. However, such an update will be required less frequently than is currently the case for seasonal vaccines, as there is evidence that changes affecting the conserved M2e region also require changes in other influenza A viral proteins because of the various functions of M2 in the virus life cycle.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>A.a.</term><def><p id="Par2">Amino acid</p></def></def-item><def-item><term>ADCC</term><def><p id="Par3">Antibody-dependent cellular cytotoxicity</p></def></def-item><def-item><term>Bac-AM2</term><def><p id="Par4">Baculovirus containing M2 from influenza virus A/Ann Arbor/6/60</p></def></def-item><def-item><term>BLS</term><def><p id="Par5"><italic>Brucella abortus</italic> lumazine synthase protein</p></def></def-item><def-item><term>CTL</term><def><p id="Par6">Cytotoxic T lymphocyte</p></def></def-item><def-item><term>ESCRT</term><def><p id="Par7">Endosomal sorting complexes required for transport</p></def></def-item><def-item><term>FcR</term><def><p id="Par8">Fc receptor</p></def></def-item><def-item><term>HA</term><def><p id="Par9">Hemagglutinin</p></def></def-item><def-item><term>HBc</term><def><p id="Par10">Hepatitis B core protein</p></def></def-item><def-item><term>IM</term><def><p id="Par11">Intramuscular immunization</p></def></def-item><def-item><term>IN</term><def><p id="Par12">Intranasal immunization</p></def></def-item><def-item><term>IP</term><def><p id="Par13">Intraperitoneal immunization</p></def></def-item><def-item><term>KLH</term><def><p id="Par14">Keyhole limpet hemocyanin</p></def></def-item><def-item><term>LLC</term><def><p id="Par15">Limited Liability Company</p></def></def-item><def-item><term>M2e</term><def><p id="Par16">Extracellular domain of the M2 protein</p></def></def-item><def-item><term>M2e5x</term><def><p id="Par17">Five M2e tandem repeats</p></def></def-item><def-item><term>M2HBc</term><def><p id="Par18">Hepatitis B core protein combined with the M2e peptide</p></def></def-item><def-item><term>M2SR</term><def><p id="Par19">M2-deficient single replication virus</p></def></def-item><def-item><term>NA</term><def><p id="Par20">Neuraminidase</p></def></def-item><def-item><term>NK</term><def><p id="Par21">Natural killer</p></def></def-item><def-item><term>NP</term><def><p id="Par22">Nucleoprotein</p></def></def-item><def-item><term>OMPC</term><def><p id="Par23">Outer membrane protein complex</p></def></def-item><def-item><term>SC</term><def><p id="Par24">Subcutaneous immunization</p></def></def-item><def-item><term>Sf9</term><def><p id="Par25">
<italic>Spodoptera frugipedra</italic>
</p></def></def-item><def-item><term>VLP</term><def><p id="Par26">Virus-like particles</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Dr. Patricia Butler for editorial assistance.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>DM: contribution to conception and design, manuscript writing; IIS: contribution to data collection and manuscript writing; LR: contribution to manuscript writing and editing. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This review was prepared with financial support of Russian Science Foundation grant 19&#x02013;15-00015.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par76">Not applicable.</p></notes><notes><title>Consent for publication</title><p id="Par77">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par78">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler-Moore</surname><given-names>JP</given-names></name><name><surname>Ernst</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Ward</surname><given-names>N</given-names></name><name><surname>Chiang</surname><given-names>SM</given-names></name><name><surname>Do</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>G</given-names></name></person-group><article-title>Monomeric M2e antigen in VesiVax((R)) liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2e</article-title><source>J Liposome Res</source><year>2017</year><volume>27</volume><issue>3</issue><fpage>210</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1080/08982104.2017.1381708</pub-id><?supplied-pmid 28922045?><pub-id pub-id-type="pmid">28922045</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>P</given-names></name><name><surname>Zylberman</surname><given-names>V</given-names></name><name><surname>Ghersi</surname><given-names>G</given-names></name><name><surname>Boado</surname><given-names>L</given-names></name><name><surname>Palacios</surname><given-names>C</given-names></name><name><surname>Goldbaum</surname><given-names>F</given-names></name><name><surname>Mattion</surname><given-names>N</given-names></name></person-group><article-title>Tandem repeats of the extracellular domain of matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><issue>5</issue><fpage>806</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.072</pub-id><?supplied-pmid 23246552?><pub-id pub-id-type="pmid">23246552</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>AM</given-names></name><name><surname>Hakansson</surname><given-names>KO</given-names></name><name><surname>Jensen</surname><given-names>BA</given-names></name><name><surname>Christensen</surname><given-names>D</given-names></name><name><surname>Andersen</surname><given-names>P</given-names></name><name><surname>Thomsen</surname><given-names>AR</given-names></name><name><surname>Christensen</surname><given-names>JP</given-names></name></person-group><article-title>Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>10</issue><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balannik</surname><given-names>V</given-names></name><name><surname>Carnevale</surname><given-names>V</given-names></name><name><surname>Fiorin</surname><given-names>G</given-names></name><name><surname>Levine</surname><given-names>BG</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name><name><surname>Degrado</surname><given-names>WF</given-names></name><name><surname>Pinto</surname><given-names>LH</given-names></name></person-group><article-title>Functional studies and modeling of pore-lining residue mutants of the influenza a virus M2 ion channel</article-title><source>Biochemistry</source><year>2010</year><volume>49</volume><issue>4</issue><fpage>696</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1021/bi901799k</pub-id><?supplied-pmid 20028125?><pub-id pub-id-type="pmid">20028125</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangaru</surname><given-names>S</given-names></name><name><surname>Lang</surname><given-names>S</given-names></name><name><surname>Schotsaert</surname><given-names>M</given-names></name><name><surname>Vanderven</surname><given-names>HA</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Kose</surname><given-names>N</given-names></name><name><surname>Bombardi</surname><given-names>R</given-names></name><name><surname>Finn</surname><given-names>JA</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name><name><surname>Gilchuk</surname><given-names>P</given-names></name><name><surname>Gilchuk</surname><given-names>I</given-names></name><name><surname>Turner</surname><given-names>HL</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Crowe</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface</article-title><source>Cell</source><year>2019</year><volume>177</volume><issue>5</issue><fpage>1136</fpage><lpage>1152 e1118</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.011</pub-id><?supplied-pmid 31100268?><pub-id pub-id-type="pmid">31100268</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumgarth</surname><given-names>N</given-names></name><name><surname>Kelso</surname><given-names>A</given-names></name></person-group><article-title>In vivo blockade of gamma interferon affects the Influenza virus-induced Humoral and the local cellular immune response in lung tissue</article-title><source>J Virol</source><year>1996</year><volume>70</volume><issue>7</issue><fpage>4411</fpage><lpage>4418</lpage><?supplied-pmid 8676464?><pub-id pub-id-type="pmid">8676464</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beale</surname><given-names>R</given-names></name><name><surname>Wise</surname><given-names>H</given-names></name><name><surname>Stuart</surname><given-names>A</given-names></name><name><surname>Ravenhill</surname><given-names>BJ</given-names></name><name><surname>Digard</surname><given-names>P</given-names></name><name><surname>Randow</surname><given-names>F</given-names></name></person-group><article-title>A LC3-interacting motif in the influenza a virus M2 protein is required to subvert autophagy and maintain virion stability</article-title><source>Cell Host Microbe</source><year>2014</year><volume>15</volume><issue>2</issue><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2014.01.006</pub-id><?supplied-pmid 24528869?><pub-id pub-id-type="pmid">24528869</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beebe</surname><given-names>DP</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Cooper</surname><given-names>NR</given-names></name></person-group><article-title>Neutralization of Influenza virus by Normal human sera: mechanisms involving antibody and complement</article-title><source>J Immunol</source><year>1983</year><volume>130</volume><issue>3</issue><fpage>1317</fpage><lpage>1322</lpage><?supplied-pmid 6822737?><pub-id pub-id-type="pmid">6822737</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlanda</surname><given-names>SF</given-names></name><name><surname>Tsvetnitsky</surname><given-names>V</given-names></name><name><surname>Donnelly</surname><given-names>JJ</given-names></name></person-group><article-title>Universal influenza vaccines: shifting to better vaccines</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><issue>26</issue><fpage>2926</fpage><lpage>2933</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.03.085</pub-id><pub-id pub-id-type="pmid">27038130</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bier</surname><given-names>K</given-names></name><name><surname>York</surname><given-names>A</given-names></name><name><surname>Fodor</surname><given-names>E</given-names></name></person-group><article-title>Cellular cap-binding proteins associate with influenza virus mRNAs</article-title><source>J Gen Virol</source><year>2011</year><volume>92</volume><issue>Pt 7</issue><fpage>1627</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1099/vir.0.029231-0</pub-id><?supplied-pmid 21402597?><pub-id pub-id-type="pmid">21402597</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>RA</given-names></name><name><surname>Rota</surname><given-names>PA</given-names></name><name><surname>Gorodkova</surname><given-names>N</given-names></name><name><surname>Klenk</surname><given-names>HD</given-names></name><name><surname>Kendal</surname><given-names>AP</given-names></name></person-group><article-title>Antibody response to the M2 protein of influenza a virus expressed in insect cells</article-title><source>J Gen Virol</source><year>1993</year><volume>74</volume><fpage>143</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-74-1-143</pub-id><?supplied-pmid 8423445?><pub-id pub-id-type="pmid">8423445</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>BJ</given-names></name><name><surname>Leser</surname><given-names>GP</given-names></name><name><surname>Jackson</surname><given-names>D</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name></person-group><article-title>The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding</article-title><source>J Virol</source><year>2008</year><volume>82</volume><issue>20</issue><fpage>10059</fpage><lpage>10070</lpage><pub-id pub-id-type="doi">10.1128/JVI.01184-08</pub-id><?supplied-pmid 18701586?><pub-id pub-id-type="pmid">18701586</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>TK</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Ng</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>CH</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name></person-group><article-title>Generation of recombinant influenza a virus without M2 ion-channel protein by introduction of a point mutation at the 5&#x02032; end of the viral intron</article-title><source>J Gen Virol</source><year>2005</year><volume>86</volume><issue>Pt 5</issue><fpage>1447</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1099/vir.0.80727-0</pub-id><?supplied-pmid 15831957?><pub-id pub-id-type="pmid">15831957</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chizhmakov</surname><given-names>IV</given-names></name><name><surname>Geraghty</surname><given-names>FM</given-names></name><name><surname>Ogden</surname><given-names>DC</given-names></name><name><surname>Hayhurst</surname><given-names>A</given-names></name><name><surname>Antoniou</surname><given-names>M</given-names></name><name><surname>Hay</surname><given-names>AJ</given-names></name></person-group><article-title>Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells</article-title><source>J Physiol</source><year>1996</year><volume>494</volume><issue>2</issue><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1996.sp021495</pub-id><?supplied-pmid 8841994?><pub-id pub-id-type="pmid">8841994</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>KJ</given-names></name><name><surname>Schepens</surname><given-names>B</given-names></name><name><surname>Moonens</surname><given-names>K</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Remaut</surname><given-names>H</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>Crystal structure of the conserved amino terminus of the extracellular domain of matrix protein 2 of Influenza a virus gripped by an antibody</article-title><source>J Virol</source><year>2016</year><volume>90</volume><issue>1</issue><fpage>611</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1128/JVI.02105-15</pub-id><?supplied-pmid 26468526?><pub-id pub-id-type="pmid">26468526</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>KJ</given-names></name><name><surname>Schepens</surname><given-names>B</given-names></name><name><surname>Seok</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Roose</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Gallardo</surname><given-names>R</given-names></name><name><surname>Van Hamme</surname><given-names>E</given-names></name><name><surname>Schymkowitz</surname><given-names>J</given-names></name><name><surname>Rousseau</surname><given-names>F</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name></person-group><article-title>Structure of the extracellular domain of matrix protein 2 of influenza a virus in complex with a protective monoclonal antibody</article-title><source>J Virol</source><year>2015</year><volume>89</volume><issue>7</issue><fpage>3700</fpage><lpage>3711</lpage><pub-id pub-id-type="doi">10.1128/JVI.02576-14</pub-id><?supplied-pmid 25609808?><pub-id pub-id-type="pmid">25609808</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Filette</surname><given-names>M</given-names></name><name><surname>Martens</surname><given-names>W</given-names></name><name><surname>Roose</surname><given-names>K</given-names></name><name><surname>Deroo</surname><given-names>T</given-names></name><name><surname>Vervalle</surname><given-names>F</given-names></name><name><surname>Bentahir</surname><given-names>M</given-names></name><name><surname>Vandekerckhove</surname><given-names>J</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>An Influenza a vaccine based on Tetrameric Ectodomain of matrix protein 2</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><issue>17</issue><fpage>11382</fpage><lpage>11387</lpage><pub-id pub-id-type="doi">10.1074/jbc.M800650200</pub-id><?supplied-pmid 18252707?><pub-id pub-id-type="pmid">18252707</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Filette</surname><given-names>M</given-names></name><name><surname>Ysenbaert</surname><given-names>T</given-names></name><name><surname>Roose</surname><given-names>K</given-names></name><name><surname>Schotsaert</surname><given-names>M</given-names></name><name><surname>Roels</surname><given-names>S</given-names></name><name><surname>Goossens</surname><given-names>E</given-names></name><name><surname>Schepens</surname><given-names>B</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>Antiserum against the conserved nine amino acid N-terminal peptide of influenza a virus matrix protein 2 is not immunoprotective</article-title><source>J Gen Virol</source><year>2011</year><volume>92</volume><issue>Pt 2</issue><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1099/vir.0.027086-0</pub-id><?supplied-pmid 20965983?><pub-id pub-id-type="pmid">20965983</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Lei</given-names></name><name><surname>Cho</surname><given-names>Ki</given-names></name><name><surname>Fiers</surname><given-names>Walter</given-names></name><name><surname>Saelens</surname><given-names>Xavier</given-names></name></person-group><article-title>M2e-Based Universal Influenza A Vaccines</article-title><source>Vaccines</source><year>2015</year><volume>3</volume><issue>1</issue><fpage>105</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.3390/vaccines3010105</pub-id><?supplied-pmid 26344949?><pub-id pub-id-type="pmid">26344949</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Ibanez</surname><given-names>LI</given-names></name><name><surname>Van den Bossche</surname><given-names>V</given-names></name><name><surname>Roose</surname><given-names>K</given-names></name><name><surname>Youssef</surname><given-names>SA</given-names></name><name><surname>de Bruin</surname><given-names>A</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>Protection against Influenza a virus challenge with M2e-displaying filamentous Escherichia coli phages</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>5</issue><fpage>e0126650</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0126650</pub-id><?supplied-pmid 25973787?><pub-id pub-id-type="pmid">25973787</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiPiazza</surname><given-names>A</given-names></name><name><surname>Richards</surname><given-names>K</given-names></name><name><surname>Batarse</surname><given-names>F</given-names></name><name><surname>Lockard</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Albrecht</surname><given-names>RA</given-names></name><name><surname>Sant</surname><given-names>AJ</given-names></name></person-group><article-title>Flow Cytometric and cytokine ELISpot approaches to characterize the cell-mediated immune response in ferrets following Influenza virus infection</article-title><source>J Virol</source><year>2016</year><volume>90</volume><issue>17</issue><fpage>7991</fpage><lpage>8004</lpage><pub-id pub-id-type="doi">10.1128/JVI.01001-16</pub-id><?supplied-pmid 27356897?><pub-id pub-id-type="pmid">27356897</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebrahimi</surname><given-names>SM</given-names></name><name><surname>Tebianian</surname><given-names>M</given-names></name></person-group><article-title>Influenza a viruses: why focusing on M2e-based universal vaccines</article-title><source>Virus Genes</source><year>2011</year><volume>42</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s11262-010-0547-7</pub-id><?supplied-pmid 21082230?><pub-id pub-id-type="pmid">21082230</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichelberger</surname><given-names>MC</given-names></name><name><surname>Wan</surname><given-names>H</given-names></name></person-group><article-title>Influenza neuraminidase as a vaccine antigen</article-title><source>Curr Top Microbiol Immunol</source><year>2015</year><volume>386</volume><fpage>275</fpage><lpage>299</lpage><?supplied-pmid 25033754?><pub-id pub-id-type="pmid">25033754</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Bakkouri</surname><given-names>K</given-names></name><name><surname>Descamps</surname><given-names>F</given-names></name><name><surname>De Filette</surname><given-names>M</given-names></name><name><surname>Smet</surname><given-names>A</given-names></name><name><surname>Festjens</surname><given-names>E</given-names></name><name><surname>Birkett</surname><given-names>A</given-names></name><name><surname>Van Rooijen</surname><given-names>N</given-names></name><name><surname>Verbeek</surname><given-names>S</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>Universal vaccine based on ectodomain of matrix protein 2 of influenza a: fc receptors and alveolar macrophages mediate protection</article-title><source>J Immunol</source><year>2011</year><volume>186</volume><issue>2</issue><fpage>1022</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902147</pub-id><?supplied-pmid 21169548?><pub-id pub-id-type="pmid">21169548</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eliasson</surname><given-names>DG</given-names></name><name><surname>El Bakkouri</surname><given-names>K</given-names></name><name><surname>Schon</surname><given-names>K</given-names></name><name><surname>Ramne</surname><given-names>A</given-names></name><name><surname>Festjens</surname><given-names>E</given-names></name><name><surname>Lowenadler</surname><given-names>B</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name><name><surname>Lycke</surname><given-names>N</given-names></name></person-group><article-title>CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><issue>9</issue><fpage>1243</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.12.027</pub-id><?supplied-pmid 18243429?><pub-id pub-id-type="pmid">18243429</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eliasson</surname><given-names>DG</given-names></name><name><surname>Omokanye</surname><given-names>A</given-names></name><name><surname>Schon</surname><given-names>K</given-names></name><name><surname>Wenzel</surname><given-names>UA</given-names></name><name><surname>Bernasconi</surname><given-names>V</given-names></name><name><surname>Bemark</surname><given-names>M</given-names></name><name><surname>Kolpe</surname><given-names>A</given-names></name><name><surname>El Bakkouri</surname><given-names>K</given-names></name><name><surname>Ysenbaert</surname><given-names>T</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name><name><surname>Lycke</surname><given-names>N</given-names></name></person-group><article-title>M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection</article-title><source>Mucosal Immunol</source><year>2018</year><volume>11</volume><issue>1</issue><fpage>273</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/mi.2017.14</pub-id><?supplied-pmid 28295019?><pub-id pub-id-type="pmid">28295019</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>SL</given-names></name></person-group><article-title>Universal Influenza vaccines: Progress in achieving broad cross-protection in vivo</article-title><source>Am J Epidemiol</source><year>2018</year><volume>187</volume><issue>12</issue><fpage>2603</fpage><lpage>2614</lpage><?supplied-pmid 30084906?><pub-id pub-id-type="pmid">30084906</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Horton</surname><given-names>MS</given-names></name><name><surname>Perry</surname><given-names>HC</given-names></name><name><surname>Citron</surname><given-names>MP</given-names></name><name><surname>Heidecker</surname><given-names>GJ</given-names></name><name><surname>Fu</surname><given-names>TM</given-names></name><name><surname>Joyce</surname><given-names>J</given-names></name><name><surname>Przysiecki</surname><given-names>CT</given-names></name><name><surname>Keller</surname><given-names>PM</given-names></name><name><surname>Garsky</surname><given-names>VM</given-names></name><name><surname>Ionescu</surname><given-names>R</given-names></name><name><surname>Rippeon</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Chastain</surname><given-names>MA</given-names></name><name><surname>Condra</surname><given-names>JH</given-names></name><name><surname>Davies</surname><given-names>ME</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Emini</surname><given-names>EA</given-names></name><name><surname>Shiver</surname><given-names>JW</given-names></name></person-group><article-title>Preclinical study of influenza virus a M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><issue>23&#x02013;24</issue><fpage>2993</fpage><lpage>3003</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.02.021</pub-id><?supplied-pmid 15297047?><pub-id pub-id-type="pmid">15297047</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Mozdzanowska</surname><given-names>K</given-names></name><name><surname>Zharikova</surname><given-names>D</given-names></name><name><surname>Hoff</surname><given-names>H</given-names></name><name><surname>Wunner</surname><given-names>W</given-names></name><name><surname>Couch</surname><given-names>RB</given-names></name><name><surname>Gerhard</surname><given-names>W</given-names></name></person-group><article-title>Influenza a virus infection engenders a poor antibody response against the ectodomain of matrix protein 2</article-title><source>Virol J</source><year>2006</year><volume>3</volume><fpage>102</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-3-102</pub-id><?supplied-pmid 17150104?><pub-id pub-id-type="pmid">17150104</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Sesma</surname><given-names>A</given-names></name><name><surname>Schulman</surname><given-names>JL</given-names></name><name><surname>Moran</surname><given-names>TM</given-names></name></person-group><article-title>A Bispecific antibody recognizing Influenza a virus M2 protein redirects effector cells to inhibit virus replication in vitro</article-title><source>J Virol</source><year>1996</year><volume>70</volume><issue>7</issue><fpage>4800</fpage><lpage>4804</lpage><?supplied-pmid 8676511?><pub-id pub-id-type="pmid">8676511</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>De Filette</surname><given-names>M</given-names></name><name><surname>El Bakkouri</surname><given-names>K</given-names></name><name><surname>Schepens</surname><given-names>B</given-names></name><name><surname>Roose</surname><given-names>K</given-names></name><name><surname>Schotsaert</surname><given-names>M</given-names></name><name><surname>Birkett</surname><given-names>A</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>M2e-based universal influenza a vaccine</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><issue>45</issue><fpage>6280</fpage><lpage>6283</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.007</pub-id><?supplied-pmid 19840661?><pub-id pub-id-type="pmid">19840661</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>T-M</given-names></name><name><surname>Freed</surname><given-names>DC</given-names></name><name><surname>Horton</surname><given-names>MS</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Citron</surname><given-names>MP</given-names></name><name><surname>Joyce</surname><given-names>JG</given-names></name><name><surname>Garsky</surname><given-names>VM</given-names></name><name><surname>Casimiro</surname><given-names>DR</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Shiver</surname><given-names>JW</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name></person-group><article-title>Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza a virus</article-title><source>Virology</source><year>2009</year><volume>385</volume><issue>1</issue><fpage>218</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2008.11.035</pub-id><?supplied-pmid 19070878?><pub-id pub-id-type="pmid">19070878</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuse</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Kamigaki</surname><given-names>T</given-names></name><name><surname>Oshitani</surname><given-names>H</given-names></name></person-group><article-title>Evolution of the M gene of the influenza a virus in different host species: large-scale sequence analysis</article-title><source>Virol J</source><year>2009</year><volume>6</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-6-67</pub-id><?supplied-pmid 19476650?><pub-id pub-id-type="pmid">19476650</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gannage</surname><given-names>M</given-names></name><name><surname>Dormann</surname><given-names>D</given-names></name><name><surname>Albrecht</surname><given-names>R</given-names></name><name><surname>Dengjel</surname><given-names>J</given-names></name><name><surname>Torossi</surname><given-names>T</given-names></name><name><surname>Ramer</surname><given-names>PC</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Strowig</surname><given-names>T</given-names></name><name><surname>Arrey</surname><given-names>F</given-names></name><name><surname>Conenello</surname><given-names>G</given-names></name><name><surname>Pypaert</surname><given-names>M</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Munz</surname><given-names>C</given-names></name></person-group><article-title>Matrix protein 2 of influenza a virus blocks autophagosome fusion with lysosomes</article-title><source>Cell Host Microbe</source><year>2009</year><volume>6</volume><issue>4</issue><fpage>367</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2009.09.005</pub-id><?supplied-pmid 19837376?><pub-id pub-id-type="pmid">19837376</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgieva</surname><given-names>ER</given-names></name><name><surname>Borbat</surname><given-names>PP</given-names></name><name><surname>Norman</surname><given-names>HD</given-names></name><name><surname>Freed</surname><given-names>JH</given-names></name></person-group><article-title>Mechanism of influenza a M2 transmembrane domain assembly in lipid membranes</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>11757</fpage><pub-id pub-id-type="doi">10.1038/srep11757</pub-id><?supplied-pmid 26190831?><pub-id pub-id-type="pmid">26190831</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianfrani</surname><given-names>&#x00421;</given-names></name><name><surname>Oseroff</surname><given-names>&#x00421;</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Chesnut</surname><given-names>RW</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><article-title>Human memory CTL response specific for Influenza a virus is broad and multispecific</article-title><source>Hum Immunol</source><year>2000</year><volume>61</volume><fpage>438</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/S0198-8859(00)00105-1</pub-id><?supplied-pmid 10773346?><pub-id pub-id-type="pmid">10773346</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandea</surname><given-names>AG</given-names></name><name><surname>Olsen</surname><given-names>OA</given-names></name><name><surname>Cox</surname><given-names>TC</given-names></name><name><surname>Renshaw</surname><given-names>M</given-names></name><name><surname>Hammond</surname><given-names>PW</given-names></name><name><surname>Chan-Hui</surname><given-names>PY</given-names></name><name><surname>Mitcham</surname><given-names>JL</given-names></name><name><surname>Cieplak</surname><given-names>W</given-names></name><name><surname>Stewart</surname><given-names>SM</given-names></name><name><surname>Grantham</surname><given-names>ML</given-names></name><name><surname>Pekosz</surname><given-names>A</given-names></name><name><surname>Kiso</surname><given-names>M</given-names></name><name><surname>Shinya</surname><given-names>K</given-names></name><name><surname>Hatta</surname><given-names>M</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Moyle</surname><given-names>M</given-names></name></person-group><article-title>Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><issue>28</issue><fpage>126658</fpage><lpage>112663</lpage><pub-id pub-id-type="doi">10.1073/pnas.0911806107</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashemi</surname><given-names>H</given-names></name><name><surname>Pouyanfard</surname><given-names>S</given-names></name><name><surname>Bandehpour</surname><given-names>M</given-names></name><name><surname>Noroozbabaei</surname><given-names>Z</given-names></name><name><surname>Kazemi</surname><given-names>B</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name><name><surname>Mokhtari-Azad</surname><given-names>T</given-names></name></person-group><article-title>Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza a virus challenge</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>9</issue><fpage>e45765</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0045765</pub-id><?supplied-pmid 23029232?><pub-id pub-id-type="pmid">23029232</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatta</surname><given-names>Y</given-names></name><name><surname>Boltz</surname><given-names>D</given-names></name><name><surname>Sarawar</surname><given-names>S</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Neumann</surname><given-names>G</given-names></name><name><surname>Bilsel</surname><given-names>P</given-names></name></person-group><article-title>M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><issue>33</issue><fpage>4177</fpage><lpage>4183</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.06.039</pub-id><?supplied-pmid 28668565?><pub-id pub-id-type="pmid">28668565</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatta</surname><given-names>Y</given-names></name><name><surname>Boltz</surname><given-names>D</given-names></name><name><surname>Sarawar</surname><given-names>S</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Neumann</surname><given-names>G</given-names></name><name><surname>Bilsel</surname><given-names>P</given-names></name></person-group><article-title>Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><issue>33</issue><fpage>5097</fpage><lpage>5103</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.06.053</pub-id><?supplied-pmid 30007825?><pub-id pub-id-type="pmid">30007825</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinen</surname><given-names>PP</given-names></name><name><surname>Rijsewijk</surname><given-names>FA</given-names></name><name><surname>de Boer-Luijtzev</surname><given-names>EA</given-names></name><name><surname>Bianchi</surname><given-names>AT</given-names></name></person-group><article-title>Vaccination of pigs with a DNA construct expressing an influenza virus M2&#x02013;nucleoprotein fusion protein exacerbates disease after challenge with influenza a virus</article-title><source>J Gen Virol</source><year>2002</year><volume>83</volume><fpage>1851</fpage><lpage>1859</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-83-8-1851</pub-id><?supplied-pmid 12124449?><pub-id pub-id-type="pmid">12124449</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helenius</surname><given-names>A</given-names></name></person-group><article-title>Unpacking the incoming Influenza virus</article-title><source>Cell</source><year>1992</year><volume>69</volume><fpage>577</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90219-3</pub-id><?supplied-pmid 1375129?><pub-id pub-id-type="pmid">1375129</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>RL</given-names></name><name><surname>Winkelstein</surname><given-names>JA</given-names></name><name><surname>Griffin</surname><given-names>DE</given-names></name></person-group><article-title>The role of complement in viral infections. III Activation of the classical and alternative complement pathways by Sindbis virus</article-title><source>J Immunol</source><year>1980</year><volume>124</volume><issue>5</issue><fpage>2507</fpage><lpage>2510</lpage><?supplied-pmid 7365263?><pub-id pub-id-type="pmid">7365263</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holsinger</surname><given-names>LJ</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name></person-group><article-title>Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds</article-title><source>Virology</source><year>1991</year><volume>183</volume><issue>1</issue><fpage>32</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(91)90115-R</pub-id><?supplied-pmid 2053285?><pub-id pub-id-type="pmid">2053285</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughey</surname><given-names>PG</given-names></name><name><surname>Roberts</surname><given-names>PC</given-names></name><name><surname>Holsinger</surname><given-names>LJ</given-names></name><name><surname>Zebedee</surname><given-names>SL</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name></person-group><article-title>Effects of antibody to the influenza a virus M2 protein on M2 surface expression and virus assembly</article-title><source>Virology</source><year>1995</year><volume>212</volume><issue>2</issue><fpage>411</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1006/viro.1995.1498</pub-id><?supplied-pmid 7571410?><pub-id pub-id-type="pmid">7571410</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huleatt</surname><given-names>JW</given-names></name><name><surname>Nakaar</surname><given-names>V</given-names></name><name><surname>Desai</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Hewitt</surname><given-names>D</given-names></name><name><surname>Jacobs</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>McDonald</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Evans</surname><given-names>RK</given-names></name><name><surname>Umlauf</surname><given-names>S</given-names></name><name><surname>Tussey</surname><given-names>L</given-names></name><name><surname>Powell</surname><given-names>TJ</given-names></name></person-group><article-title>Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><issue>2</issue><fpage>201</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.10.062</pub-id><?supplied-pmid 18063235?><pub-id pub-id-type="pmid">18063235</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchinson</surname><given-names>EC</given-names></name><name><surname>Charles</surname><given-names>PD</given-names></name><name><surname>Hester</surname><given-names>SS</given-names></name><name><surname>Thomas</surname><given-names>B</given-names></name><name><surname>Trudgian</surname><given-names>D</given-names></name><name><surname>Martinez-Alonso</surname><given-names>M</given-names></name><name><surname>Fodor</surname><given-names>E</given-names></name></person-group><article-title>Conserved and host-specific features of influenza virion architecture</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>4816</fpage><pub-id pub-id-type="doi">10.1038/ncomms5816</pub-id><?supplied-pmid 25226414?><pub-id pub-id-type="pmid">25226414</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchinson</surname><given-names>EC</given-names></name><name><surname>Curran</surname><given-names>MD</given-names></name><name><surname>Read</surname><given-names>EK</given-names></name><name><surname>Gog</surname><given-names>JR</given-names></name><name><surname>Digard</surname><given-names>P</given-names></name></person-group><article-title>Mutational analysis of cis-acting RNA signals in segment 7 of influenza a virus</article-title><source>J Virol</source><year>2008</year><volume>82</volume><issue>23</issue><fpage>11869</fpage><lpage>11879</lpage><pub-id pub-id-type="doi">10.1128/JVI.01634-08</pub-id><?supplied-pmid 18815307?><pub-id pub-id-type="pmid">18815307</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichinohe</surname><given-names>T</given-names></name><name><surname>Pang</surname><given-names>IK</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><article-title>Influenza virus activates inflammasomes via its intracellular M2 ion channel</article-title><source>Nat Immunol</source><year>2010</year><volume>11</volume><issue>5</issue><fpage>404</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1038/ni.1861</pub-id><?supplied-pmid 20383149?><pub-id pub-id-type="pmid">20383149</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Ninomiya</surname><given-names>A</given-names></name><name><surname>Obuchi</surname><given-names>M</given-names></name><name><surname>Odagiri</surname><given-names>T</given-names></name></person-group><article-title>Influenza B virus BM2 protein is a crucial component for incorporation of viral ribonucleoprotein complex into virions during virus assembly</article-title><source>J Virol</source><year>2004</year><volume>78</volume><issue>20</issue><fpage>11007</fpage><lpage>11015</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.20.11007-11015.2004</pub-id><?supplied-pmid 15452221?><pub-id pub-id-type="pmid">15452221</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Gorman</surname><given-names>OT</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Bean</surname><given-names>WJ</given-names></name><name><surname>Webster</surname><given-names>RJ</given-names></name></person-group><article-title>Evolutionary analysis of the influenza a virus M gene with comparison of the M1 and M2 proteins</article-title><source>J Virol</source><year>1991</year><volume>65</volume><fpage>5491</fpage><lpage>5498</lpage><?supplied-pmid 1895397?><pub-id pub-id-type="pmid">1895397</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jameson</surname><given-names>J</given-names></name><name><surname>Cruz</surname><given-names>J</given-names></name><name><surname>Terajima</surname><given-names>M</given-names></name><name><surname>Ennis</surname><given-names>FA</given-names></name></person-group><article-title>Human CD8+ and CD4+ T lymphocyte memory to Influenza a viruses of swine and avian</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>7578</fpage><lpage>7583</lpage><?supplied-pmid 10358215?><pub-id pub-id-type="pmid">10358215</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegerlehner</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>N</given-names></name><name><surname>Storni</surname><given-names>T</given-names></name><name><surname>Bachmann</surname><given-names>MF</given-names></name></person-group><article-title>Influenza a vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><issue>9</issue><fpage>5598</fpage><lpage>5605</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.9.5598</pub-id><?supplied-pmid 15100303?><pub-id pub-id-type="pmid">15100303</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kacskovics</surname><given-names>I</given-names></name></person-group><article-title>Fc receptors in livestock species</article-title><source>Vet Immunol Immunopathol</source><year>2004</year><volume>102</volume><issue>4</issue><fpage>351</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2004.06.008</pub-id><?supplied-pmid 15541789?><pub-id pub-id-type="pmid">15541789</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. Brief Bioinform. 2017.</mixed-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Kwon</surname><given-names>YM</given-names></name><name><surname>O</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Choi</surname><given-names>JG</given-names></name><name><surname>Wang</surname><given-names>BZ</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group><article-title>Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection</article-title><source>Antiviral Res</source><year>2013</year><volume>99</volume><issue>3</issue><fpage>328</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.06.010</pub-id><?supplied-pmid 23811283?><pub-id pub-id-type="pmid">23811283</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>YN</given-names></name><name><surname>Ko</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Kwon</surname><given-names>YM</given-names></name><name><surname>Hwang</surname><given-names>HS</given-names></name><name><surname>Song</surname><given-names>JM</given-names></name><name><surname>Song</surname><given-names>BM</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Choi</surname><given-names>JG</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>Quan</surname><given-names>FS</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group><article-title>Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection</article-title><source>Molecular therapy : the journal of the American Society of Gene Therapy</source><year>2014</year><volume>22</volume><issue>7</issue><fpage>1364</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1038/mt.2014.33</pub-id><pub-id pub-id-type="pmid">24590045</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MC</given-names></name><name><surname>Song</surname><given-names>JM</given-names></name><name><surname>O</surname><given-names>E</given-names></name><name><surname>Kwon</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group><article-title>Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus</article-title><source>Mol Ther</source><year>2013</year><volume>21</volume><issue>2</issue><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.246</pub-id><?supplied-pmid 23247101?><pub-id pub-id-type="pmid">23247101</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolpe</surname><given-names>A</given-names></name><name><surname>Schepens</surname><given-names>B</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>M2-based influenza vaccines: recent advances and clinical potential</article-title><source>Expert Rev Vaccines</source><year>2017</year><volume>16</volume><issue>2</issue><fpage>123</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1080/14760584.2017.1240041</pub-id><?supplied-pmid 27653543?><pub-id pub-id-type="pmid">27653543</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolpe</surname><given-names>A</given-names></name><name><surname>Schepens</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Staeheli</surname><given-names>P</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>Passively transferred M2e-specific monoclonal antibody reduces influenza a virus transmission in mice</article-title><source>Antivir Res</source><year>2018</year><volume>158</volume><fpage>244</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2018.08.017</pub-id><?supplied-pmid 30179634?><pub-id pub-id-type="pmid">30179634</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><article-title>Emerging influenza viruses and the prospect of a universal influenza virus vaccine</article-title><source>Biotechnol J</source><year>2015</year><volume>10</volume><issue>5</issue><fpage>690</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1002/biot.201400393</pub-id><?supplied-pmid 25728134?><pub-id pub-id-type="pmid">25728134</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Advances in the development of influenza virus vaccines</article-title><source>Nat Rev Drug Discov</source><year>2015</year><volume>14</volume><issue>3</issue><fpage>167</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/nrd4529</pub-id><?supplied-pmid 25722244?><pub-id pub-id-type="pmid">25722244</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Influenza virus hemagglutinin stalk-based antibodies and vaccines</article-title><source>Curr Opin Virol</source><year>2013</year><volume>3</volume><issue>5</issue><fpage>521</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2013.07.007</pub-id><?supplied-pmid 23978327?><pub-id pub-id-type="pmid">23978327</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Pica</surname><given-names>N</given-names></name><name><surname>Hai</surname><given-names>R</given-names></name><name><surname>Margine</surname><given-names>I</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies</article-title><source>J Virol</source><year>2013</year><volume>87</volume><issue>12</issue><fpage>6542</fpage><lpage>6550</lpage><pub-id pub-id-type="doi">10.1128/JVI.00641-13</pub-id><?supplied-pmid 23576508?><pub-id pub-id-type="pmid">23576508</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Choppin</surname><given-names>PW</given-names></name></person-group><article-title>Identification of a second protein (M2) encoded by RNA segment 7 of Influenza virus</article-title><source>Virology</source><year>1981</year><volume>112</volume><fpage>729</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(81)90317-2</pub-id><?supplied-pmid 7257188?><pub-id pub-id-type="pmid">7257188</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Choppin</surname><given-names>PW</given-names></name></person-group><article-title>Segment 8 of the influenza virus genome is unique in coding for two polypeptides</article-title><source>Biochemistry</source><year>1979</year><volume>76</volume><issue>10</issue><fpage>4908</fpage><lpage>4912</lpage></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Lai</surname><given-names>CJ</given-names></name></person-group><article-title>Conservation of the Influenza virus membrane protein (M1) amino acid sequence and an open Reading frame of RNA segment 7 encoding a second protein (M2) in HlN1 and H3N2 strains</article-title><source>Virology</source><year>1981</year><volume>112</volume><fpage>746</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(81)90319-6</pub-id><?supplied-pmid 7257189?><pub-id pub-id-type="pmid">7257189</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Lai</surname><given-names>CJ</given-names></name></person-group><article-title>Spliced and Unspliced messenger RNAs synthesized from cloned Influenza virus M DNA in an SV40 vector: expression of the Influenza virus membrane protein (M1)</article-title><source>Virology</source><year>1982</year><volume>123</volume><fpage>237</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(82)90258-6</pub-id><?supplied-pmid 6184879?><pub-id pub-id-type="pmid">6184879</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Zebedee</surname><given-names>SL</given-names></name><name><surname>Richardson</surname><given-names>CD</given-names></name></person-group><article-title>Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface</article-title><source>Cell</source><year>1985</year><volume>40</volume><fpage>627</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(85)90211-9</pub-id><?supplied-pmid 3882238?><pub-id pub-id-type="pmid">3882238</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leclerc</surname><given-names>D</given-names></name><name><surname>Rivest</surname><given-names>M</given-names></name><name><surname>Babin</surname><given-names>C</given-names></name><name><surname>Lopez-Macias</surname><given-names>C</given-names></name><name><surname>Savard</surname><given-names>P</given-names></name></person-group><article-title>A novel M2e based flu vaccine formulation for dogs</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>10</issue><fpage>e77084</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0077084</pub-id><?supplied-pmid 24098576?><pub-id pub-id-type="pmid">24098576</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YN</given-names></name><name><surname>Kim</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>YT</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group><article-title>Mechanisms of cross-protection by Influenza virus M2-based vaccines</article-title><source>Immune Network</source><year>2015</year><volume>15</volume><issue>5</issue><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.4110/in.2015.15.5.213</pub-id><?supplied-pmid 26557805?><pub-id pub-id-type="pmid">26557805</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YN</given-names></name><name><surname>Lee</surname><given-names>YT</given-names></name><name><surname>Kim</surname><given-names>MC</given-names></name><name><surname>Hwang</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group><article-title>Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination</article-title><source>Immunology</source><year>2014</year><volume>143</volume><issue>2</issue><fpage>300</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1111/imm.12310</pub-id><?supplied-pmid 24773389?><pub-id pub-id-type="pmid">24773389</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YT</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Ko</surname><given-names>EJ</given-names></name><name><surname>Kim</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>YN</given-names></name><name><surname>Hwang</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Jung</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Santos</surname><given-names>J</given-names></name><name><surname>Perez</surname><given-names>DR</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group><article-title>Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles</article-title><source>Virology</source><year>2019</year><volume>529</volume><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2019.01.017</pub-id><?supplied-pmid 30685658?><pub-id pub-id-type="pmid">30685658</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YT</given-names></name><name><surname>Ko</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>YN</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group><article-title>Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses</article-title><source>PLoS One</source><year>2018</year><volume>13</volume><issue>1</issue><fpage>e0190868</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0190868</pub-id><?supplied-pmid 29324805?><pub-id pub-id-type="pmid">29324805</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiding</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Martinsson</surname><given-names>J</given-names></name><name><surname>DeGrado</surname><given-names>WF</given-names></name><name><surname>Arskold</surname><given-names>SP</given-names></name></person-group><article-title>Proton and cation transport activity of the M2 proton channel from influenza a virus</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><issue>35</issue><fpage>15409</fpage><lpage>15414</lpage><pub-id pub-id-type="doi">10.1073/pnas.1009997107</pub-id><?supplied-pmid 20713739?><pub-id pub-id-type="pmid">20713739</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letunic</surname><given-names>I</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name></person-group><article-title>Interactive tree of life (iTOL) v4: recent updates and new developments</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>W1</issue><fpage>W256</fpage><lpage>W259</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz239</pub-id><?supplied-pmid 30931475?><pub-id pub-id-type="pmid">30931475</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y-H</given-names></name></person-group><article-title>N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication</article-title><source>FEMS Immunol Med Microbiol</source><year>2003</year><volume>35</volume><issue>2</issue><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/S0928-8244(03)00009-9</pub-id><?supplied-pmid 12628550?><pub-id pub-id-type="pmid">12628550</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zou</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name></person-group><article-title>Monoclonal antibodies recognizing EVETPIRN epitope of influenza a virus M2 protein could protect mice from lethal influenza a virus challenge</article-title><source>Immunol Lett</source><year>2004</year><volume>93</volume><issue>2&#x02013;3</issue><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2004.03.003</pub-id><?supplied-pmid 15158608?><pub-id pub-id-type="pmid">15158608</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zou</surname><given-names>P</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name></person-group><article-title>Sequence comparison between the extracellular domain of M2 protein human and avian influenza a virus provides new information for bivalent influenza vaccine design</article-title><source>Microbes Infect</source><year>2005</year><volume>7</volume><issue>2</issue><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2004.10.006</pub-id><?supplied-pmid 15777646?><pub-id pub-id-type="pmid">15777646</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotfi</surname><given-names>Z</given-names></name><name><surname>Golchin</surname><given-names>M</given-names></name><name><surname>Khalili-Yazdi</surname><given-names>A</given-names></name><name><surname>Khalili</surname><given-names>M</given-names></name></person-group><article-title>Immunological properties of the SLLTEVET epitope of Influenza a virus in multiple display on filamentous M13 phage</article-title><source>Comp Immunol Microbiol Infect Dis</source><year>2019</year><volume>65</volume><fpage>76</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.cimid.2019.05.004</pub-id><?supplied-pmid 31300131?><pub-id pub-id-type="pmid">31300131</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzoor</surname><given-names>Rashid</given-names></name><name><surname>Igarashi</surname><given-names>Manabu</given-names></name><name><surname>Takada</surname><given-names>Ayato</given-names></name></person-group><article-title>Influenza A Virus M2 Protein: Roles from Ingress to Egress</article-title><source>International Journal of Molecular Sciences</source><year>2017</year><volume>18</volume><issue>12</issue><fpage>2649</fpage><pub-id pub-id-type="doi">10.3390/ijms18122649</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margine</surname><given-names>I</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Hai</surname><given-names>R</given-names></name><name><surname>Heaton</surname><given-names>NS</given-names></name><name><surname>Tan</surname><given-names>GS</given-names></name><name><surname>Andrews</surname><given-names>SA</given-names></name><name><surname>Runstadler</surname><given-names>JA</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name><name><surname>Albrecht</surname><given-names>RA</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza a viruses</article-title><source>J Virol</source><year>2013</year><volume>87</volume><issue>19</issue><fpage>10435</fpage><lpage>10446</lpage><pub-id pub-id-type="doi">10.1128/JVI.01715-13</pub-id><?supplied-pmid 23903831?><pub-id pub-id-type="pmid">23903831</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCown</surname><given-names>MF</given-names></name><name><surname>Pekosz</surname><given-names>A</given-names></name></person-group><article-title>The influenza a virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging</article-title><source>J Virol</source><year>2005</year><volume>79</volume><issue>6</issue><fpage>3595</fpage><lpage>3605</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.6.3595-3605.2005</pub-id><?supplied-pmid 15731254?><pub-id pub-id-type="pmid">15731254</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><mixed-citation publication-type="other">Mcgeoch D., Fellnert P. and Newton C. Influenza virus genome consists of eight distinct RNA species Biochemistry 73(9):3045&#x02013;3049, 1976.</mixed-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>SB</given-names></name><name><surname>Holzer</surname><given-names>B</given-names></name><name><surname>Hemmink</surname><given-names>JD</given-names></name><name><surname>Salguero</surname><given-names>FJ</given-names></name><name><surname>Schwartz</surname><given-names>JC</given-names></name><name><surname>Agatic</surname><given-names>G</given-names></name><name><surname>Cameroni</surname><given-names>E</given-names></name><name><surname>Guarino</surname><given-names>B</given-names></name><name><surname>Porter</surname><given-names>E</given-names></name><name><surname>Rijal</surname><given-names>P</given-names></name><name><surname>Townsend</surname><given-names>A</given-names></name><name><surname>Charleston</surname><given-names>B</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Tchilian</surname><given-names>E</given-names></name></person-group><article-title>Therapeutic Administration of Broadly Neutralizing FI6 antibody reveals lack of interaction between human IgG1 and pig fc receptors</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>865</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00865</pub-id><?supplied-pmid 29740451?><pub-id pub-id-type="pmid">29740451</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mould</surname><given-names>JA</given-names></name><name><surname>Paterson</surname><given-names>RG</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Ohigashi</surname><given-names>Y</given-names></name><name><surname>Venkataraman</surname><given-names>P</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Pinto</surname><given-names>LH</given-names></name></person-group><article-title>Influenza B virus BM2 protein has Ion Channel activity that conducts protons across membranes</article-title><source>Dev Cell</source><year>2003</year><volume>5</volume><issue>1</issue><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/S1534-5807(03)00190-4</pub-id><?supplied-pmid 12852861?><pub-id pub-id-type="pmid">12852861</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Music</surname><given-names>N</given-names></name><name><surname>Reber</surname><given-names>AJ</given-names></name><name><surname>Kim</surname><given-names>MC</given-names></name><name><surname>York</surname><given-names>IA</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group><article-title>Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><issue>4</issue><fpage>466</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.12.023</pub-id><?supplied-pmid 26709639?><pub-id pub-id-type="pmid">26709639</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neirynck</surname><given-names>S</given-names></name><name><surname>Deroo</surname><given-names>T</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name><name><surname>Vanlandschoot</surname><given-names>P</given-names></name><name><surname>Jou</surname><given-names>WM</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name></person-group><article-title>A universal influenza a vaccine based on the extracellular domain of the M2 protein</article-title><source>Nat Med</source><year>1999</year><volume>5</volume><issue>10</issue><fpage>1157</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1038/13484</pub-id><?supplied-pmid 10502819?><pub-id pub-id-type="pmid">10502819</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Ihata</surname><given-names>A</given-names></name><name><surname>Watabe</surname><given-names>S</given-names></name><name><surname>Okada</surname><given-names>E</given-names></name><name><surname>Yamakawa</surname><given-names>T</given-names></name><name><surname>Hamajima</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Nakazawa</surname><given-names>M</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Ohnari</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Xin</surname><given-names>KQ</given-names></name></person-group><article-title>Protective immunity against influenza a virus induced by immunization with DNA plasmid containing influenza M gene</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>3681</fpage><lpage>3691</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00078-0</pub-id><?supplied-pmid 11395202?><pub-id pub-id-type="pmid">11395202</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Schulman</surname><given-names>JL</given-names></name></person-group><article-title>Differences in RNA patterns of Influenza a viruses</article-title><source>J Virol</source><year>1976</year><volume>17</volume><issue>3</issue><fpage>876</fpage><lpage>884</lpage><?supplied-pmid 1255862?><pub-id pub-id-type="pmid">1255862</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JK</given-names></name><name><surname>Taubenberger</surname><given-names>JK</given-names></name></person-group><article-title>Universal Influenza vaccines: to dream the possible dream?</article-title><source>ACS Infect Dis</source><year>2016</year><volume>2</volume><issue>1</issue><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.5b00146</pub-id><?supplied-pmid 26977452?><pub-id pub-id-type="pmid">26977452</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Seo</surname><given-names>YB</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Im</surname><given-names>SJ</given-names></name><name><surname>Seo</surname><given-names>SH</given-names></name><name><surname>Song</surname><given-names>MS</given-names></name><name><surname>Choi</surname><given-names>YK</given-names></name><name><surname>Sung</surname><given-names>YC</given-names></name></person-group><article-title>Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>33</issue><fpage>5481</fpage><lpage>5487</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.062</pub-id><?supplied-pmid 21664216?><pub-id pub-id-type="pmid">21664216</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paterson</surname><given-names>RG</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Ohigashi</surname><given-names>Y</given-names></name><name><surname>Pinto</surname><given-names>LH</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name></person-group><article-title>Influenza B virus BM2 protein is an oligomeric integral membrane protein expressed at the cell surface</article-title><source>Virology</source><year>2003</year><volume>306</volume><issue>1</issue><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/S0042-6822(02)00083-1</pub-id><?supplied-pmid 12620792?><pub-id pub-id-type="pmid">12620792</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pejoski</surname><given-names>D</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Rockman</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>LE</given-names></name><name><surname>Jackson</surname><given-names>DC</given-names></name></person-group><article-title>A lipopeptide based on the M2 and HA proteins of influenza a viruses induces protective antibody</article-title><source>Immunol Cell Biol</source><year>2010</year><volume>88</volume><issue>5</issue><fpage>605</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1038/icb.2010.15</pub-id><?supplied-pmid 20177411?><pub-id pub-id-type="pmid">20177411</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrie</surname><given-names>JG</given-names></name><name><surname>Malosh</surname><given-names>RE</given-names></name><name><surname>Cheng</surname><given-names>CK</given-names></name><name><surname>Ohmit</surname><given-names>SE</given-names></name><name><surname>Martin</surname><given-names>ET</given-names></name><name><surname>Johnson</surname><given-names>E</given-names></name><name><surname>Truscon</surname><given-names>R</given-names></name><name><surname>Eichelberger</surname><given-names>MC</given-names></name><name><surname>Gubareva</surname><given-names>LV</given-names></name><name><surname>Fry</surname><given-names>AM</given-names></name><name><surname>Monto</surname><given-names>AS</given-names></name></person-group><article-title>The household Influenza vaccine effectiveness study: lack of antibody response and protection following receipt of 2014-2015 Influenza vaccine</article-title><source>Clin Infect Dis</source><year>2017</year><volume>65</volume><issue>10</issue><fpage>1644</fpage><lpage>1651</lpage><pub-id pub-id-type="doi">10.1093/cid/cix608</pub-id><?supplied-pmid 29020179?><pub-id pub-id-type="pmid">29020179</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petukhova</surname><given-names>N</given-names></name><name><surname>Gasanova</surname><given-names>T</given-names></name><name><surname>Stepanova</surname><given-names>L</given-names></name><name><surname>Rusova</surname><given-names>O</given-names></name><name><surname>Potapchuk</surname><given-names>M</given-names></name><name><surname>Korotkov</surname><given-names>A</given-names></name><name><surname>Skurat</surname><given-names>E</given-names></name><name><surname>Tsybalova</surname><given-names>L</given-names></name><name><surname>Kiselev</surname><given-names>O</given-names></name><name><surname>Ivanov</surname><given-names>P</given-names></name><name><surname>Atabekov</surname><given-names>J</given-names></name></person-group><article-title>Immunogenicity and protective efficacy of candidate universal Influenza a Nanovaccines produced in plants by tobacco mosaic virus-based vectors</article-title><source>Curr Pharm Des</source><year>2013</year><volume>19</volume><issue>31</issue><fpage>5587</fpage><lpage>5600</lpage><pub-id pub-id-type="doi">10.2174/13816128113199990337</pub-id><?supplied-pmid 23394564?><pub-id pub-id-type="pmid">23394564</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>LH</given-names></name><name><surname>Holsinger</surname><given-names>LJ</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name></person-group><article-title>Influenza virus M2 protein has ion channel activity</article-title><source>Cell</source><year>1992</year><volume>69</volume><fpage>517</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90452-I</pub-id><?supplied-pmid 1374685?><pub-id pub-id-type="pmid">1374685</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pons</surname><given-names>MW</given-names></name></person-group><article-title>A reexamination of influenza single- and double-stranded RNAs by gel electrophoresis</article-title><source>Virology</source><year>1976</year><volume>69</volume><fpage>789</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(76)90508-0</pub-id><?supplied-pmid 1258370?><pub-id pub-id-type="pmid">1258370</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>EL</given-names></name><name><surname>Mitcham</surname><given-names>JL</given-names></name><name><surname>Koller</surname><given-names>TD</given-names></name><name><surname>Bonavia</surname><given-names>A</given-names></name><name><surname>Usner</surname><given-names>DW</given-names></name><name><surname>Balaratnam</surname><given-names>G</given-names></name><name><surname>Fredlund</surname><given-names>P</given-names></name><name><surname>Swiderek</surname><given-names>KM</given-names></name></person-group><article-title>Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza</article-title><source>J Infect Dis</source><year>2015</year><volume>211</volume><issue>7</issue><fpage>1038</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu539</pub-id><?supplied-pmid 25281755?><pub-id pub-id-type="pmid">25281755</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robb</surname><given-names>NC</given-names></name><name><surname>Fodor</surname><given-names>E</given-names></name></person-group><article-title>The accumulation of influenza a virus segment 7 spliced mRNAs is regulated by the NS1 protein</article-title><source>J Gen Virol</source><year>2012</year><volume>93</volume><issue>Pt 1</issue><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1099/vir.0.035485-0</pub-id><?supplied-pmid 21918006?><pub-id pub-id-type="pmid">21918006</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossman</surname><given-names>JS</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Leser</surname><given-names>GP</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name></person-group><article-title>Influenza virus M2 protein mediates ESCRT-independent membrane scission</article-title><source>Cell</source><year>2010</year><volume>142</volume><issue>6</issue><fpage>902</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.08.029</pub-id><?supplied-pmid 20850012?><pub-id pub-id-type="pmid">20850012</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saelens</surname><given-names>Xavier</given-names></name></person-group><article-title>The Role of Matrix Protein 2 Ectodomain in the Development of Universal Influenza Vaccines</article-title><source>The Journal of Infectious Diseases</source><year>2019</year><volume>219</volume><issue>Supplement_1</issue><fpage>S68</fpage><lpage>S74</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz003</pub-id><?supplied-pmid 30715367?><pub-id pub-id-type="pmid">30715367</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarawar</surname><given-names>S</given-names></name><name><surname>Hatta</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Dias</surname><given-names>P</given-names></name><name><surname>Neumann</surname><given-names>G</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Bilsel</surname><given-names>P</given-names></name></person-group><article-title>M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><issue>42</issue><fpage>5090</fpage><lpage>5098</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.08.061</pub-id><?supplied-pmid 27595896?><pub-id pub-id-type="pmid">27595896</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnell</surname><given-names>JR</given-names></name><name><surname>Chou</surname><given-names>JJ</given-names></name></person-group><article-title>Structure and mechanism of the M2 proton channel of influenza a virus</article-title><source>Nature</source><year>2008</year><volume>451</volume><issue>7178</issue><fpage>591</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1038/nature06531</pub-id><?supplied-pmid 18235503?><pub-id pub-id-type="pmid">18235503</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schotsaert</surname><given-names>M</given-names></name><name><surname>Ysenbaert</surname><given-names>T</given-names></name><name><surname>Smet</surname><given-names>A</given-names></name><name><surname>Schepens</surname><given-names>B</given-names></name><name><surname>Vanderschaeghe</surname><given-names>D</given-names></name><name><surname>Stegalkina</surname><given-names>S</given-names></name><name><surname>Vogel</surname><given-names>TU</given-names></name><name><surname>Callewaert</surname><given-names>N</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>Long-lasting cross-protection against Influenza a by neuraminidase and M2e-based immunization strategies</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>24402</fpage><pub-id pub-id-type="doi">10.1038/srep24402</pub-id><?supplied-pmid 27072615?><pub-id pub-id-type="pmid">27072615</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>SR</given-names></name><name><surname>Krug</surname><given-names>RM</given-names></name></person-group><article-title>Surprising function of the three Influenza viral polymerase proteins: selective protection of viral mRNAs against the cap-snatching reaction catalyzed by the same polymerase proteins</article-title><source>Virology</source><year>1996</year><volume>226</volume><fpage>430</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1006/viro.1996.0673</pub-id><?supplied-pmid 8955065?><pub-id pub-id-type="pmid">8955065</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>SR</given-names></name><name><surname>Nemeroff</surname><given-names>ME</given-names></name><name><surname>Krug</surname><given-names>RM</given-names></name></person-group><article-title>The choice of alternative 5&#x02032; splice sites in influenza virus M1 mRNA is regulated by the viral polymerase complex</article-title><source>Proc Natl Acad Sci U S A</source><year>1995</year><volume>92</volume><fpage>6324</fpage><lpage>6328</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.14.6324</pub-id><?supplied-pmid 7541537?><pub-id pub-id-type="pmid">7541537</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simhadri</surname><given-names>VR</given-names></name><name><surname>Dimitrova</surname><given-names>M</given-names></name><name><surname>Mariano</surname><given-names>JL</given-names></name><name><surname>Zenarruzabeitia</surname><given-names>O</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Ozawa</surname><given-names>T</given-names></name><name><surname>Muraguchi</surname><given-names>A</given-names></name><name><surname>Kishi</surname><given-names>H</given-names></name><name><surname>Eichelberger</surname><given-names>MC</given-names></name><name><surname>Borrego</surname><given-names>F</given-names></name></person-group><article-title>A human anti-M2 antibody mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and cytokine secretion by resting and cytokine-Preactivated natural killer (NK) cells</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>4</issue><fpage>e0124677</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0124677</pub-id><?supplied-pmid 25915748?><pub-id pub-id-type="pmid">25915748</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>GJ</given-names></name><name><surname>Vijaykrishna</surname><given-names>D</given-names></name><name><surname>Bahl</surname><given-names>J</given-names></name><name><surname>Lycett</surname><given-names>SJ</given-names></name><name><surname>Worobey</surname><given-names>M</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name><name><surname>Ma</surname><given-names>SK</given-names></name><name><surname>Cheung</surname><given-names>CL</given-names></name><name><surname>Raghwani</surname><given-names>J</given-names></name><name><surname>Bhatt</surname><given-names>S</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name></person-group><article-title>Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza a epidemic</article-title><source>Nature</source><year>2009</year><volume>459</volume><issue>7250</issue><fpage>1122</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1038/nature08182</pub-id><?supplied-pmid 19516283?><pub-id pub-id-type="pmid">19516283</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>BZ</given-names></name><name><surname>Park</surname><given-names>KM</given-names></name><name><surname>Rooijen</surname><given-names>NV</given-names></name><name><surname>Quan</surname><given-names>FS</given-names></name><name><surname>Kim</surname><given-names>MC</given-names></name><name><surname>Jin</surname><given-names>HT</given-names></name><name><surname>Pekosz</surname><given-names>A</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group><article-title>Influenza virus-like particles containing M2 induce broadly cross protective immunity</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>1</issue><fpage>14538</fpage><lpage>145348</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0014538</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sridhar</surname><given-names>S</given-names></name><name><surname>Begom</surname><given-names>S</given-names></name><name><surname>Bermingham</surname><given-names>A</given-names></name><name><surname>Hoschler</surname><given-names>K</given-names></name><name><surname>Adamson</surname><given-names>W</given-names></name><name><surname>Carman</surname><given-names>W</given-names></name><name><surname>Bean</surname><given-names>T</given-names></name><name><surname>Barclay</surname><given-names>W</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Lalvani</surname><given-names>A</given-names></name></person-group><article-title>Cellular immune correlates of protection against symptomatic pandemic influenza</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><issue>10</issue><fpage>1305</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1038/nm.3350</pub-id><pub-id pub-id-type="pmid">24056771</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stauffer</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Nebioglu</surname><given-names>F</given-names></name><name><surname>Heilig</surname><given-names>R</given-names></name><name><surname>Picotti</surname><given-names>P</given-names></name><name><surname>Helenius</surname><given-names>A</given-names></name></person-group><article-title>Stepwise priming by acidic pH and a high K+ concentration is required for efficient uncoating of influenza a virus cores after penetration</article-title><source>J Virol</source><year>2014</year><volume>88</volume><issue>22</issue><fpage>13029</fpage><lpage>13046</lpage><pub-id pub-id-type="doi">10.1128/JVI.01430-14</pub-id><?supplied-pmid 25165113?><pub-id pub-id-type="pmid">25165113</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepanova</surname><given-names>LA</given-names></name><name><surname>Mardanova</surname><given-names>ES</given-names></name><name><surname>Shuklina</surname><given-names>MA</given-names></name><name><surname>Blokhina</surname><given-names>EA</given-names></name><name><surname>Kotlyarov</surname><given-names>RY</given-names></name><name><surname>Potapchuk</surname><given-names>MV</given-names></name><name><surname>Kovaleva</surname><given-names>AA</given-names></name><name><surname>Vidyaeva</surname><given-names>IG</given-names></name><name><surname>Korotkov</surname><given-names>AV</given-names></name><name><surname>Eletskaya</surname><given-names>EI</given-names></name><name><surname>Ravin</surname><given-names>NV</given-names></name><name><surname>Tsybalova</surname><given-names>LM</given-names></name></person-group><article-title>Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes</article-title><source>J Biomed Sci</source><year>2018</year><volume>25</volume><issue>1</issue><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s12929-018-0433-5</pub-id><?supplied-pmid 29631629?><pub-id pub-id-type="pmid">29631629</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoloff</surname><given-names>GA</given-names></name><name><surname>Caparros-Wanderley</surname><given-names>W</given-names></name></person-group><article-title>Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes</article-title><source>Eur J Immunol</source><year>2007</year><volume>37</volume><issue>9</issue><fpage>2441</fpage><lpage>2449</lpage><pub-id pub-id-type="doi">10.1002/eji.200737254</pub-id><?supplied-pmid 17668898?><pub-id pub-id-type="pmid">17668898</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stouffer</surname><given-names>AL</given-names></name><name><surname>Acharya</surname><given-names>R</given-names></name><name><surname>Salom</surname><given-names>D</given-names></name><name><surname>Levine</surname><given-names>AS</given-names></name><name><surname>Di Costanzo</surname><given-names>L</given-names></name><name><surname>Soto</surname><given-names>CS</given-names></name><name><surname>Tereshko</surname><given-names>V</given-names></name><name><surname>Nanda</surname><given-names>V</given-names></name><name><surname>Stayrook</surname><given-names>S</given-names></name><name><surname>DeGrado</surname><given-names>WF</given-names></name></person-group><article-title>Structural basis for the function and inhibition of an influenza virus proton channel</article-title><source>Nature</source><year>2008</year><volume>451</volume><issue>7178</issue><fpage>596</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1038/nature06528</pub-id><?supplied-pmid 18235504?><pub-id pub-id-type="pmid">18235504</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Pekosz</surname><given-names>A</given-names></name><name><surname>Shuck</surname><given-names>K</given-names></name><name><surname>Pinto</surname><given-names>LH</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name></person-group><article-title>Influenza a virus M2 Ion Channel activity is essential for efficient replication in tissue culture</article-title><source>J Virol</source><year>2002</year><volume>76</volume><issue>3</issue><fpage>1391</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.3.1391-1399.2002</pub-id><?supplied-pmid 11773413?><pub-id pub-id-type="pmid">11773413</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talbot</surname><given-names>HK</given-names></name><name><surname>Rock</surname><given-names>MT</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Tussey</surname><given-names>L</given-names></name><name><surname>Kavita</surname><given-names>U</given-names></name><name><surname>Shanker</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>AR</given-names></name><name><surname>Taylor</surname><given-names>DN</given-names></name></person-group><article-title>Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><issue>12</issue><fpage>e14442</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0014442</pub-id><?supplied-pmid 21203437?><pub-id pub-id-type="pmid">21203437</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Zaitseva</surname><given-names>F</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Pinto</surname><given-names>LH</given-names></name></person-group><article-title>The gate of the influenza virus M2 proton channel is formed by a single tryptophan residue</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><issue>42</issue><fpage>39880</fpage><lpage>39886</lpage><pub-id pub-id-type="doi">10.1074/jbc.M206582200</pub-id><?supplied-pmid 12183461?><pub-id pub-id-type="pmid">12183461</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tompkins</surname><given-names>SM</given-names></name><name><surname>Zhao</surname><given-names>ZS</given-names></name><name><surname>Lo</surname><given-names>CY</given-names></name><name><surname>Misplon</surname><given-names>JA</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Hogan</surname><given-names>RJ</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Benton</surname><given-names>KA</given-names></name><name><surname>Tumpey</surname><given-names>TM</given-names></name><name><surname>Epstein</surname><given-names>SL</given-names></name></person-group><article-title>Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1</article-title><source>Emerg Infect Dis</source><year>2007</year><volume>13</volume><issue>3</issue><fpage>426</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.3201/eid1303.061125</pub-id><?supplied-pmid 17552096?><pub-id pub-id-type="pmid">17552096</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topham</surname><given-names>DI</given-names></name><name><surname>Tripp</surname><given-names>RA</given-names></name><name><surname>Doherty</surname><given-names>PC</given-names></name></person-group><article-title>CD8+ T cells clear Influenza virus by Perforin or Fas-dependent processes</article-title><source>J Immunol</source><year>1997</year><volume>159</volume><issue>11</issue><fpage>5197</fpage><lpage>5200</lpage><?supplied-pmid 9548456?><pub-id pub-id-type="pmid">9548456</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treanor</surname><given-names>JJ</given-names></name><name><surname>Tierney</surname><given-names>EL</given-names></name><name><surname>Zebedee</surname><given-names>SL</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Murphy</surname><given-names>BR</given-names></name></person-group><article-title>Passively transferred monoclonal antibody to the M2 protein inhibits Influenza a virus replication in mice</article-title><source>J Virol</source><year>1990</year><volume>64</volume><issue>3</issue><fpage>1375</fpage><lpage>1377</lpage><?supplied-pmid 2304147?><pub-id pub-id-type="pmid">2304147</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsybalova</surname><given-names>LM</given-names></name><name><surname>Stepanova</surname><given-names>LA</given-names></name><name><surname>Kuprianov</surname><given-names>VV</given-names></name><name><surname>Blokhina</surname><given-names>EA</given-names></name><name><surname>Potapchuk</surname><given-names>MV</given-names></name><name><surname>Korotkov</surname><given-names>AV</given-names></name><name><surname>Gorshkov</surname><given-names>AN</given-names></name><name><surname>Kasyanenko</surname><given-names>MA</given-names></name><name><surname>Ravin</surname><given-names>NV</given-names></name><name><surname>Kiselev</surname><given-names>OI</given-names></name></person-group><article-title>Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: broad protective efficacy of particles carrying four copies of M2e</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><issue>29</issue><fpage>3398</fpage><lpage>3406</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.073</pub-id><?supplied-pmid 25976545?><pub-id pub-id-type="pmid">25976545</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turley</surname><given-names>CB</given-names></name><name><surname>Rupp</surname><given-names>RE</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>DN</given-names></name><name><surname>Wolfson</surname><given-names>J</given-names></name><name><surname>Tussey</surname><given-names>L</given-names></name><name><surname>Kavita</surname><given-names>U</given-names></name><name><surname>Stanberry</surname><given-names>L</given-names></name><name><surname>Shaw</surname><given-names>A</given-names></name></person-group><article-title>Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>32</issue><fpage>5145</fpage><lpage>5152</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.041</pub-id><?supplied-pmid 21624416?><pub-id pub-id-type="pmid">21624416</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><mixed-citation publication-type="other">Van den Hoecke S, Ehrhardt K, Kolpe A, El Bakkouri K, Deng L, Grootaert H, Schoonooghe S, Smet A, Bentahir M, Roose K, Schotsaert M, Schepens B, Callewaert N, Nimmerjahn F, Staeheli P, Hengel H, Saelens X. Hierarchical and Redundant Roles of Activating FcgammaRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies. J Virol. 2017;91(7). 10.1128/JVI.02500-16.</mixed-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkataraman</surname><given-names>P</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Pinto</surname><given-names>LH</given-names></name></person-group><article-title>Chemical rescue of histidine selectivity filter mutants of the M2 ion channel of influenza a virus</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><issue>22</issue><fpage>21463</fpage><lpage>21472</lpage><pub-id pub-id-type="doi">10.1074/jbc.M412406200</pub-id><?supplied-pmid 15784624?><pub-id pub-id-type="pmid">15784624</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Holle</surname><given-names>TA</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name></person-group><article-title>Influenza and antibody-dependent cellular cytotoxicity</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>1457</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01457</pub-id><pub-id pub-id-type="pmid">31316510</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Pielak</surname><given-names>RM</given-names></name><name><surname>McClintock</surname><given-names>MA</given-names></name><name><surname>Chou</surname><given-names>JJ</given-names></name></person-group><article-title>Solution structure and functional analysis of the influenza B proton channel</article-title><source>Nat Struct Mol Biol</source><year>2009</year><volume>16</volume><issue>12</issue><fpage>1267</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1707</pub-id><?supplied-pmid 19898475?><pub-id pub-id-type="pmid">19898475</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Song</surname><given-names>A</given-names></name><name><surname>Levin</surname><given-names>J</given-names></name><name><surname>Dennis</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>NJ</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Koriazova</surname><given-names>L</given-names></name><name><surname>Madura</surname><given-names>L</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Mikayama</surname><given-names>T</given-names></name><name><surname>Kubo</surname><given-names>RT</given-names></name><name><surname>Sarawar</surname><given-names>S</given-names></name><name><surname>Cheroutre</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name></person-group><article-title>Therapeutic potential of a fully human monoclonal antibody against influenza a virus M2 protein</article-title><source>Antivir Res</source><year>2008</year><volume>80</volume><issue>2</issue><fpage>168</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2008.06.002</pub-id><?supplied-pmid 18598723?><pub-id pub-id-type="pmid">18598723</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Pang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Greene</surname><given-names>CM</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name></person-group><article-title>Potential impact of B lineage mismatch on trivalent influenza vaccine effectiveness during the 2015-2016 influenza season among nursery school children in Suzhou</article-title><source>China Hum Vaccin Immunother</source><year>2018</year><volume>14</volume><issue>3</issue><fpage>630</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1397868</pub-id><?supplied-pmid 29090968?><pub-id pub-id-type="pmid">29090968</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>McCarthy</surname><given-names>KR</given-names></name><name><surname>Kuraoka</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Onodera</surname><given-names>T</given-names></name><name><surname>Tonouchi</surname><given-names>K</given-names></name><name><surname>Caradonna</surname><given-names>TM</given-names></name><name><surname>Bajic</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>McGee</surname><given-names>CE</given-names></name><name><surname>Sempowski</surname><given-names>GD</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Urick</surname><given-names>P</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name></person-group><article-title>Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism</article-title><source>Cell</source><year>2019</year><volume>177</volume><issue>5</issue><fpage>1124</fpage><lpage>1135 e1116</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.03.048</pub-id><?supplied-pmid 31100267?><pub-id pub-id-type="pmid">31100267</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Kida</surname><given-names>H</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name></person-group><article-title>Influenza a virus can undergo multiple cycles of replication without M2 ion channel activity</article-title><source>J Virol</source><year>2001</year><volume>75</volume><issue>12</issue><fpage>5656</fpage><lpage>5662</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.12.5656-5662.2001</pub-id><?supplied-pmid 11356973?><pub-id pub-id-type="pmid">11356973</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wharton</surname><given-names>SA</given-names></name><name><surname>Belshe</surname><given-names>RB</given-names></name><name><surname>Skehel</surname><given-names>JJ</given-names></name><name><surname>Hay</surname><given-names>AJ</given-names></name></person-group><article-title>Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine</article-title><source>J Gen Virol</source><year>1994</year><volume>75</volume><issue>Pt 4</issue><fpage>945</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-75-4-945</pub-id><?supplied-pmid 8151308?><pub-id pub-id-type="pmid">8151308</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><mixed-citation publication-type="other">WHO. Antigenic and genetic characteristics of zoonotic influenza viruses and candidate vaccine viruses developed for potential use in human vaccines. 22 February 2018. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/entity/influenza/vaccines/virus/201802_zoonotic_vaccinevirusupdate.pdf?ua=1">http://www.who.int/entity/influenza/vaccines/virus/201802_zoonotic_vaccinevirusupdate.pdf?ua=1</ext-link>. 2018.</mixed-citation></ref><ref id="CR134"><label>134.</label><mixed-citation publication-type="other">WHO. Tables on clinical evaluation of influenza vaccines. Pandemic and potentially pandemic influenza vaccines. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/entity/immunization/diseases/influenza/Table_clinical_evaluation_influenza_pandemic.xlsx?ua=1">http://www.who.int/entity/immunization/diseases/influenza/Table_clinical_evaluation_influenza_pandemic.xlsx?ua=1</ext-link>. 2018.</mixed-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>G</given-names></name><name><surname>Fields</surname><given-names>S</given-names></name></person-group><article-title>Cloning of influenza cDNA into M13: the sequence of the RNA segment encoding the a/PR/8/34 matrix protein</article-title><source>Nucleic Acids Res</source><year>1980</year><volume>8</volume><issue>9</issue><fpage>1965</fpage><lpage>1974</lpage><pub-id pub-id-type="doi">10.1093/nar/8.9.1965</pub-id><?supplied-pmid 6927841?><pub-id pub-id-type="pmid">6927841</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>HM</given-names></name><name><surname>Hutchinson</surname><given-names>EC</given-names></name><name><surname>Jagger</surname><given-names>BW</given-names></name><name><surname>Stuart</surname><given-names>AD</given-names></name><name><surname>Kang</surname><given-names>ZH</given-names></name><name><surname>Robb</surname><given-names>N</given-names></name><name><surname>Schwartzman</surname><given-names>LM</given-names></name><name><surname>Kash</surname><given-names>JC</given-names></name><name><surname>Fodor</surname><given-names>E</given-names></name><name><surname>Firth</surname><given-names>AE</given-names></name><name><surname>Gog</surname><given-names>JR</given-names></name><name><surname>Taubenberger</surname><given-names>JK</given-names></name><name><surname>Digard</surname><given-names>P</given-names></name></person-group><article-title>Identification of a novel splice variant form of the influenza a virus M2 ion channel with an antigenically distinct ectodomain</article-title><source>PLoS Pathog</source><year>2012</year><volume>8</volume><issue>11</issue><fpage>e1002998</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002998</pub-id><?supplied-pmid 23133386?><pub-id pub-id-type="pmid">23133386</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><mixed-citation publication-type="other">Wohlgemuth N, Lane AP, Pekosz A. Influenza A Virus M2 Protein Apical Targeting Is Required for Efficient Virus Replication. J Virol. 2018;92(22). 10.1128/JVI.01425-18.</mixed-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>JH</given-names></name><name><surname>Yuan</surname><given-names>XY</given-names></name><name><surname>Huang</surname><given-names>WS</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name></person-group><article-title>Characterization of immunity induced by M2e of influenza virus</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><issue>52</issue><fpage>8868</fpage><lpage>8873</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.09.056</pub-id><?supplied-pmid 18061317?><pub-id pub-id-type="pmid">18061317</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zebedee</surname><given-names>SL</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name></person-group><article-title>Growth restriction of influenza a virus by M2 protein antibody is genetically linked to the M1 protein</article-title><source>Proc Natl Acad Sci U S A</source><year>1989</year><volume>86</volume><issue>3</issue><fpage>1061</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1073/pnas.86.3.1061</pub-id><?supplied-pmid 2915973?><pub-id pub-id-type="pmid">2915973</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zebedee</surname><given-names>SL</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name></person-group><article-title>Influenza a virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions</article-title><source>J Virol</source><year>1988</year><volume>62</volume><fpage>2762</fpage><lpage>2772</lpage><?supplied-pmid 2455818?><pub-id pub-id-type="pmid">2455818</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Ru</surname><given-names>Z</given-names></name><name><surname>Kou</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Lone</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>BZ</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus</article-title><source>Virol J</source><year>2010</year><volume>7</volume><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1186/1743-422X-7-151</pub-id><?supplied-pmid 20624292?><pub-id pub-id-type="pmid">20624292</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zharikova</surname><given-names>D</given-names></name><name><surname>Mozdzanowska</surname><given-names>K</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Gerhard</surname><given-names>W</given-names></name></person-group><article-title>Influenza type a virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2</article-title><source>J Virol</source><year>2005</year><volume>79</volume><issue>11</issue><fpage>6644</fpage><lpage>6654</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.11.6644-6654.2005</pub-id><?supplied-pmid 15890902?><pub-id pub-id-type="pmid">15890902</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Reed</surname><given-names>C</given-names></name><name><surname>Blair</surname><given-names>PJ</given-names></name><name><surname>Katz</surname><given-names>JM</given-names></name><name><surname>Hancock</surname><given-names>K</given-names></name><collab>Influenza Serology Working G</collab></person-group><article-title>Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans</article-title><source>J Infect Dis</source><year>2014</year><volume>209</volume><issue>7</issue><fpage>986</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit811</pub-id><?supplied-pmid 24325965?><pub-id pub-id-type="pmid">24325965</pub-id></element-citation></ref></ref-list></back></article>